

CURRICULUM VITAE

DANIELA MATEI

***Diana Princess of Wales Professor in Cancer Research
Chief, Division of Reproductive Science in Medicine
Feinberg School of Medicine, Northwestern University
Department of Obstetrics and Gynecology
Department of Medicine***

Address: 303 E. Superior St.
Lurie Cancer Center
Suite 04-107
Chicago, IL 60611
Tel: 312-503-4853
Daniela.matei@northwestern.edu
daniela.matei@nm.org

EDUCATION:

GRADUATE

University of Medicine and Pharmacy Carol Davila Bucharest, Romania	M.D.	9/1992
--	------	--------

UNDERGRADUATE

Gheorghe Lazar College Sibiu, Romania	Baccalaureate Mathematics/Physics	9/1986
--	--------------------------------------	--------

POST GRADUATE:

State University of New York at Stony Brook Stony Brook, NY	Internship/Residency	6/1996
University of California at Los Angeles Los Angeles, CA	Fellowship	6/2002
Northwestern University Kellogg School of Management, Evanston, IL	Certificate Executive Leadership	10/2023

APPOINTMENTS:

ACADEMIC

Indiana University School of Medicine Department of Medicine Division of Hematology/Oncology	Assistant Professor	11/2002 - 7/2008
Department of Obstetrics & Gynecology	Assistant Professor	11/2002 - 7/2008
Department of Biochemistry & Molecular Biology	Assistant Professor	4/2007 - 7/2008
Department of Medicine	Associate Professor with tenure	7/2008 – 7/2014

Department of Medicine
Division of Hematology-Oncology

Professor with tenure 7/2014-12/31/2015

Northwestern University Feinberg School of Medicine

Department of Obstetrics and Gynecology
Division of Gynecology Oncology

Professor- with tenure 1/1/2016-present

Department of Medicine
Division of Hematology Oncology

Professor 1/1/2016-present

Chief, Division of Reproductive Science in Medicine 12/1/2020-present

NON-ACADEMIC (i.e. administrative, hospital or corporate appointments)

	Title	Date
Indiana University Hospital 12/31/2015 Indianapolis, IN	Staff physician	11/2002 –
Richard Roudebush VA Hospital Indianapolis, IN	Staff physician	11/2002– 12/31/2015
Wishard Memorial Hospital Indianapolis, IN	Staff physician	11/2002– 12/31/2015
Indiana University Cancer Center	Member	9/2002 – 12/31/2015
Indiana University Melvin and Bren Simon Cancer Center Experimental & Developmental Therapeutics Program	Co-Leader	9/2007 – 12/31/2015
Walther Oncology Center	Member	6/2004 - 6/2009
Northwestern Memorial Hospital 250 E. Huron St. Chicago, IL 60611	Staff physician	1/2016-present
Northwestern Medical Group 675 N. St. Clair St. Galter 21	Staff Physician	1/2016-present
Jesse Brown VA Hospital Chicago, IL	Staff physician	2/2016-present
Robert H Lurie Comprehensive Cancer Center	Member	2/2016-present
Robert H Lurie Comprehensive Cancer Center Translational Research in Solid Tumors	Co-Leader	12/2017-07/2023
Robert H Lurie Comprehensive Cancer Center Translational Research in Malignancies	Leader	07/2023-present
Robert H. Lurie Comprehensive Cancer Center Translational Bridge Program	Director	4/2016-present

LICENSURE, CERTIFICATION, SPECIALTY BOARD STATUS:

Physician License Illinois	036.138970	Exp. 7/31/2026
Physician License Indiana	01056559A	Exp. 6/30/16
Controlled Substance Registration Certificate	01056559B	Exp. 12/30/15
DEA Registration	BM5002059	Exp. 1/31/20
Internal Medicine, Board Certification	1996	
Oncology, Board Certification	2003	
Hematology, Board Certification	2003	
Oncology Board Re-certification	2013	
Oncology Board Re-certification	2023	

I) PROFESSIONAL ORGANIZATION MEMBERSHIPS:

American Society of Clinical Oncology (Member)	1999 - Present
American Association for Cancer Research (Member)	2002 - Present
Department of Defense Ovarian Cancer Academy (Member)	2019 - 2023
Gynecology Oncology Group; now NRG Oncology	
Phase I Committee (Member)	2004 - 2006
Developmental Therapeutics Committee (DT) (Member)	2004 - 2016
Committee for Experimental Medicine (CEM) (Member)	2009 - 2022
Ovarian Cancer Committee (Member)	2017-Present
Data Safety and Monitoring Board (DSMB) (Member)	2011 - 2014
Safety Review Committee (SRC) (Member)	2011 - Present
Big Ten Consortium-Gynecology Oncology Group (Member)	2014 - Present
Hoosier Cancer Research Network (Member)	2004 - Present
HCRN Gynecological Oncology Committee (Chair)	2006 - 2015
American College of Physicians (Associate Member)	1997 - 1999
American Society of Hematology (Associate Member)	1999 - 2002
American Society for Biochemistry and Molecular Biology (Member)	2006 - 2008

PROFESSIONAL HONORS AND AWARDS:

Faculty Award	Granted By	Date Awarded
Young Investigator Award Ranked as the Top Junior Investigator Department of Medicine/School of Medicine	Indiana University	2007
Travel Award.	ASCO/NCI/EORTC	2008
Trailblazer Award for Research Recognizes Top Mid-Career Investigator	IUPUI	2011
William and Sarah Fisher Young Investigator Award recognizes outstanding oncology research	Hoosier Research Cancer	2014
Best Doctor	Selected by peers	2013-2015
Diana Princess of Wales Professorship	Lurie Cancer Center	2016-Present
Task Force Steering Committee for Ovarian Cancer Elected Member	National Cancer Institute	2012-2017
NRG—Best Paper 2018	NRG Oncology	2018
Harry Long Transdisciplinary Award	Society of Gynecologic Oncology	2022
Senior Clinician Investigator Award	US Department of Veterans Affairs	2024

Training Awards:

Summa cum Laude	Gheorghe Lazar College	1986
-----------------	------------------------	------

Ranked first of graduation class (320 students)		
Class President and Student Member of the University Senate	Carol Davila University	1990
National Merit Scholarship	Carol Davila University	1990-1991
Summa cum Laude	Carol Davila University	1992
Ranked first of graduation class (650 students)		
Stanley Wallace Prize for Residents		1995
Resident presentation at ACP - New York Chapter		
National Research Service Award Recipient	NIH	2000-2002
Institutional training grant: NIH: 5-T32-CA09297		
Excellence in Research Award	UCLA	2002
Hematology Oncology Fellowship		
Top Presentation, GlaxoSmithKline National Oncology	Fellows Forum	2002
<u>Other Awards:</u>		
Prize for Poetry	Annals of Internal Medicine	2012

II) **PUBLICATIONS:**
Scopus H-Index: 60

Note: Mentee's name is underlined, where applicable

Refereed

- 1) **Matei D**, Enserro D, Randall ME, Mutch D, Small W, DiSilvestro PA, Spirtos NM, et al; Long term follow-up and overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy for locally advanced endometrial carcinoma, *Journal of Clinical Oncology* 2025, doi: 10.1200/JCO.24.01121. Online ahead of print. PMID: 39700442
Highlighted in ASCO Post, MedPage Today, Cancer Network, Oncodaily
- 2) Wang Y, Frederick J, Medina KI, Bartom ET, Almossalha LM, Zhang Y, Wodarczyk G, Huang H, Ye IC, Gong R, Dunton CL, Duval A, Gonzalez PC, Pritchard J, Carinato J, Topchu I, Li J, Ji Z, Adli M, Backman V, **Matei D**; Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells, *Advanced Science*, 07 March 2025.
Highlighted in Feinberg News
- 3) **Matei D**; Comment on Study NRG258: Limitations and Future Directions, *Journal of Clinical Oncology*, 2025, *in press*
- 4) S. M. Lamperis, K. M. McMahon, A. E. Calvert, J. S. Rink, K. Vasan, M. R. Pandkar, E. U. Crentsil, Z. R. Chalmers, N. R. McDonald, C. J. Kosmala, M. G. Bonini, **D. Matei**, L. I. Gordon, N. S. Chandel, C. S. Thaxton; CRISPR Screen Reveals Simultaneous Targeted Mechanism to Reduce Cancer Cell Selenium and Increase Lipid Oxidation to Induce Ferroptosis; *PNAS*, 2025 *in press*
- 5) Clements A, Enserro D, Strickland KC, Previs R, **Matei D**, Mutch D, Powell M, Klopp A, Miller DS, Small W Jr, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse free survival and overall survival: Ancillary analysis of GOG-0258; *Gynecol Oncol*. 2025 Feb; 193:119-129. PMID: 39854806
- 6) Valdivia A, Isac A, Cardenas H, Zhao G, Zhang Y, Huang H, Wei JJ, Cuello-Fredes M, Kato S, Gómez-Valenzuela F, Gourronc FA, Klingelutz AJ, **Matei D**. Complement activation at the interface between adipocytes and cancer cells drives tumor progression, *JCI Insight*. 2025 Feb 18:e184935. Online ahead of print. PMID: 39964754
- 7) Huang H, Keathley R, Kim U, Cardenas H, Xie P, Wei JJ, Lengyel E, Nephew KP, Zhao G, Fu Z, Barber, E, Kocherginsky M, Bae-Jump V, Zhang B, **Matei D**, Comparative transcriptomic, epigenomic and immunological analyses identify drivers of disparity in high-grade serous ovarian cancer; *NPJ Genome Medicine*, 2024 Dec 2; 9(1):64
- 8) Wang Y, Duval A, Adli M, **Matei D**; Biology Informs Therapy in Ovarian Cancer, *Journal of Clinical Investigation*, 2024, [134\(1\)](#):e174013.
- 9) Wang Y, Situ, X, Cardenas H, Siu E, Alhunayan, S, Keathley R, Tanner E, Wei JJ, Tan Y, Dessai C, Cheng JX, **Matei, D**; Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer; *Clinical Cancer Research*, Volume 30, Issue 6, Pages 1175 - 1188 15 March 2024
- 10) Liu J, Berchuck A, Backes FJ, ...**Matei D**, et al. NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2024;22(8):512-519. doi:10.6004/jnccn.2024.0052
- 11) Y Wang, A E. Calvert, H Cardenas, J S. Rink, D Nahotko, C., W Qiang, E Ndukwe, F Chen, R Keathley, Y Zhang, Ji-Xin Cheng, C. Shad Thaxton, **D Matei**; Nanoparticle Targeting in Chemo-Resistant Ovarian Cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance; *Advanced Science*, 2024, 11, 2305212

Highlighted in *Feinberg News*

- 12) Zhang Y, Wang Y, Zhao G, Orsulic S, **Matei D**; Metabolic dependencies and targets in ovarian cancer, *Pharmacology and Therapeutics*, 2023, 245, 108413
- 13) Valdivia A, Vagadia P, Guo G, O'Brien E, **Matei D***, Schiltz GE*; Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2); *J. Med. Chem.* 2023, 66, 14, 9445–9465 *co-corresponding author
- 14) Huang H, Zhao G, Cardenas H, Valdivia AF, Wang Y, **Matei D**; N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase, *Molecular Cancer Therapeutics*, 2023, 22 (3), 393-405.
- 15) Zhang Y, Wang Y, Valdivia AF, Hao H, **Matei D**; DOT1 L Regulates Ovarian Cancer Stem Cells by Activating β -catenin Signaling, *Molecular Cancer Research*, 21(20 140-154, 2023
- 16) Keathley R, Kocherginsky M, Davuluri R, **Matei D**; Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer, *Cancers*, 2023, 15(14), 3649
- 17) Zhang Y, Wang Y, Zhao G, Tanner E, Adli M, **Matei D**; FOXK2 Promotes Ovarian Cancer Stemness by Regulating the Unfolded Protein Response Pathway, *Journal of Clinical Investigation*, 2022, 132(10), e151591

Highlighted in *Feinberg News*

- 18) Zhao G, Tan Y, Cardenas H, ...Cheng JX, **Matei D**; Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids; *Proceedings of the National Academy of Sciences of the United States of America*, 2022, 119(41), e2203480119

Highlighted in *Feinberg News*

- 19) Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, ..., Davuluri RV, Kocherginsky M, Zhang B, **Matei D**; Epigenetic Priming Enhances Anti-Tumor Immunity in Platinum Resistant Ovarian Cancer; *Journal of Clinical Investigation*, 2022, 132 (14): e157410

Highlighted in *Feinberg News*

- 20) Tan Y, Li J, Zhao G, Huang KG, Cardenas H, Wang Y, **Matei D***, Ji-Xin Cheng*; Metabolic Reprogramming from Glycolysis to Fatty Acid Uptake and beta-Oxidation in Platinum-Resistant Cancer Cells, *Nature Communications*, 2022, 31 (10, 4554, *co-corresponding
- 21) Roque D and **Matei D**; Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion; *Journal of Clinical Oncology*, 2022, 40(9), 924-926
- 22) Sima LE, **Matei D**, Condello, S; The Outside-In Journey of Tissue Transglutaminase in Cancer; *Cells*, 2022, 11(11), 1779
- 23) Bollu L, Bommi P, ...**Matei D**, ...Schiltz G, Wainwright D, Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degradar for Glioblastoma, *J Med Chem*, 65 (23), 15642-15662, 2022
- 24) Condello S, Prasad M, Atwani R, **Matei D**; Tissue transglutaminase activates integrin-linked kinase and β -catenin in ovarian cancer; *Journal of Biological Chemistry*, 2022, 298(8), 102242
- 25) Barber EL, Chen S, Pineda MJ, Robertson SE, Hill EK, Teoh D, Schilder J, O'Shea KL, Kocherginsky M, Zhang B, **Matei D**. Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Cancer: A Phase II trial of the Big Ten Research Consortium, *Cancer Res Commun.* 2022 Oct;2(10):1293-1303. doi: 10.1158/2767-9764.crc-22-0147. Epub 2022 Oct 28.
- 26) Towner M, Novak K, Chae YK, **Matei D**; Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma; *Gynecologic Oncology Reports*, 2022, 42, 101039
- 27) Towner M, Kim JJ, Simon MA, **Matei D**, Roque D; Disparities in gynecologic cancer incidence, treatment, and survival: a narrative review of outcomes among black and white women in the United States; *International Journal of Gynecological Cancer*, 2022, 32(7), pp. 931–938
- 28) Lheureux S, **Matei D**, Konstantinopoulos PA, ...Brooks DG, Fleming GF; Translational Randomized Phase II Trial of Cabozantinib in Combination with Nivolumab in Advanced

- Recurrent or Metastatic Endometrial Cancer, *Journal of Immunotherapy of Cancer*, 2022, 10 (3), e004233
- 29) Matulonis UA, Huang HQ, Filiaci VL, ... **Matei D**, Wenzel LB: Patient Reported Outcomes for Cisplatin and Radiation followed by Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel for Locally Advanced Endometrial Carcinoma: An NRG Oncology Study, *Gynecologic Oncology*, 2022, 164 (2), pp 428-436
 - 30) Armstrong, D; Alvarez, RD; Backes, FJ, Bakkum-Gamez, J; Barroilhet, L., **Matei D**, ... Hang, L; Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines, *JNCCN*, 2022, 20 (9), 973-980
 - 31) Wang Y, Zhao G, Condello S, Huang H, Cardenas H, Tanner EJ, Wei JJ, Ji Y, Li J, Tan Y, Davuluri RV, Peter ME, Cheng JX, and **Matei D**, Frizzled-7 identifies platinum-tolerant ovarian cancer cells susceptible to ferroptosis, *Cancer Res*, 2021, 81(2) 384-399.
 - 32) Barber E and **Matei D**: Immunotherapy in Ovarian Cancer: We are Not There Yet; *Lancet Oncology*, 2021; Jul 22 (7): 903-905
 - 33) Sima LE, Chen S, Cardenas H, Zhao G, Wang Y, Ivan C, Huang H, Zhang B, **Matei D**, Loss of Host Tissue Transglutaminase Boosts Anti-Tumor T Cell Immunity by Altering STAT1/STAT3 Phosphorylation, *Journal of Immunotherapy of Cancer*, 2021, 9(9), e002682
 - 34) Patel M, Wang Y, Bartom E, Dhir R, Nephew KP, **Matei D**, Murman AE, Lengyel E, Peter ME; The ration of toxic-to-nontoxic miRNAs predicts platinum sensitivity in ovarian cancer; *Cancer Research*, 2021 August, 81 (15), 3985-4000
 - 35) Huang H, Wang Y, Kandpal M, Zhao G, Cardenas H, Ji Y, Chaparala A, Tanner EJ, Chen J, Davuluri RV, **Matei D**. FTO-Dependent N^6 -Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling; *Cancer Res*. 2020 Aug 15;80(16):3200-3214.
 - 36) Cowan M, Swetzig WM, Adorno Cruz V, ..., Kocherginsky M, **Matei D**; Efficacy and Safety of Tivozanib in Recurrent Platinum-Resistant Ovarian Fallopian tube or Primary Peritoneal Cancer, an NCCN Phase II Trial, *Gynecologic Oncology*, 2021, 163 (1), 57-63
 - 37) **Matei D**, Nephew KP. Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes; *Cancer Res*. 2020 Sep 15;80(18):3775-3785.
 - 38) Zhuge M, Huang KC, Lee HJ, Jiang Y. Tan Y, Lin H, Dong PT, Zhao, G, **Matei, D**, Yang, Q, Cheng JX, Ultrasensitive Vibrational Imaging of Retinoids by Visible Pre-resonance Stimulated Raman Scattering Microscopy, *Advanced Science*, 2021, 8 (9), 2003136.
 - 39) Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, EINaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, **Matei D**, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Eng H AM.; Ovarian Cancer, Version 2.2020; *J Natl Compr Canc Netw*. 2021;19(2):191-226.
 - 40) Dhani NC, Hirte HW, Wang L, Burnier JV, Jain A, Butler MO, Welch S, Fleming GF, Hurteau J, Matsuo K, **Matei D**, Jimenez W, Johnston C, Cristea M, Tonkin K, Ghatage P, Lheureux S, Mehta A, Quintos J, Tan Q, Kamel-Reid S, Ludkovski O, Tsao MS, Wright JJ, Oza AM. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86); *Clin Cancer Res*. 2020 Jun 1;26(11):2477-2486.
 - 41) Cardenas H; Fang F, Jiang G; Perkins SM; Zhang C; Emerson RE, Hutchins G, Keer H, Liu Y; **Matei D**; Nephew KP; Methylomic Signatures of Acquired Platinum Resistance in High Grade Serous Ovarian Cancer; *Epigenetics*, 2020.
 - 42) Li Z, An R, Swetzig WR, Kanis M, Nwani N, Turek J, **Matei D**, and Nolte D; Intracellular Optical Doppler Phenotypes of Chemosensitivity in Human Epithelial Ovarian Cancer, *Scientific Reports*, 2020, 10 (1), 17354

- 43) Chiorean EG, Perkins SM, Strother RM, Younger A, Funke JM, Shahda SG, Hahn NM, Sandrasegaran K, Jones DR, Skaar TC, Schneider BP, Sweeney CJ, **Matei D**. Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors; *Mol Cancer Ther*. 2020 Oct;19(10):2155-2162.
- 44) Lathia J, Liu H, **Matei D**: The Clinical Impact of Cancer Stem Cells, *The Oncologist*, 2020 Feb; 25(2): 123–131
- 45) **Matei D**, Filiaci G, Randall Mem Mutch D, Steinhoff MM, DiSilvestro PA, Miller D: Adjuvant Chemotherapy/Radiation for Locally Advanced Endometrial Cancer, **N Engl J Med**. 2019 Jun 13;380(24):2317-2326. doi: 10.1056/NEJMoa1813181. PMID: 31189035
Highlighted in ASCO Post, MD Alert, Physician Weekly, NCI Cancer Blog, Medscape, Healio, Cancer Network, Up to Date, Drugs.com, Feinberg News, etc
- 46) Sima LE, Yakubov B, Zhang S, Condello S, Grigorescu AA, Nwani NG, Chen L, Schiltz GE, Arvanitis C, Zhang ZY, **Matei D**.: Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin *Mol Cancer Ther*. 2019 Jun;18(6):1057-1068.
- 47) Zhao G, Cardenas H, **Matei D**: Ovarian Cancer-Why lipids matter; *Cancers*, 2019, 11 (12) 1870.
- 48) Wang J, Thomas M, Lin P, Cheng J-X, **Matei DE**, Wei A; SiRNA Delivery Using Dithiocarbamate-Anchored Oligonucleotides on Gold Nanorods; *Bioconjugate Chemistry*, 2019, 30 (2), 443-453.
- 49) Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganessian A, Naim S, Hao Y, Keer H, Azab M, **Matei D**; A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer, *Clin Cancer Res*. 2020, 26(5), pp. 1009–1016; PMID:31831561
- 50) Cardenas H, Jiang G, Thomes Peppin J, Nephew K, Parker B, Condello S, Nakshatri H, Chakravarti D, Li Y, **Matei D**: Interferon- γ Signaling is Associated with BRCA1 Loss-of-Function Mutations in High Grade Serous Ovarian Cancer; *Nature Precision Oncology*, 2019, 6, 3:32; PMID: 31840082
- 51) Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, EINaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, **Matei D**, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Eng H AM.; NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019; *J Natl Compr Canc Netw*. 2019 Aug 1;17(8):896-909.
- 52) Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, Zhang B. CD73: an emerging checkpoint for cancer immunotherapy. *Immunotherapy*. 2019 Aug;11(11):983-997.
- 53) Nwani NG, Condello S, Wang Y, Swetzig WM, Barber E, Hurley T, **Matei D**. A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer; *Cancers (Basel)*. 2019 Apr 8;11(4).
- 54) Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, **Matei D**, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.; *Lancet Oncol*. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4.
Highlighted in Feinberg News, ASCO Post, etc
- 55) Goodman CR, Hatoum S, Seagle BL, Donnelly ED, Barber EL, Shahabi S, **Matei D**, Strauss JB. Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer; *Gynecol Oncol*. 2019 Apr;153(1):41-48.

- 56) Bulun SE, Wan Y, **Matei D**. Epithelial Mutations in Endometriosis: Link to Ovarian Cancer; *Endocrinology*. **2019** Mar 1;160(3):626-638.
- 57) Saygin C, **Matei D**, Majeti R, Reizes O, Lathia JD. Targeting Cancer Stemness in the Clinic: From Hype to Hope; *Cell Stem Cell*. **2019** Jan 3;24(1):25-40.
- 58) Cowan M, Strauss JB, Barber EL, **Matei D**. Updates on adjuvant chemotherapy and radiation therapy for endometrial cancer. *Curr Opin Obstet Gynecol*. **2019** Feb;31(1):31-37.
- 59) Nwani NG, Sima LE, Nieves-Neira W, Matei D: Targeting the microenvironment in high grade serous ovarian cancer, *Cancers (Basel)*, 2018, 10 (8).
- 60) Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, **Matei D**. Pembrolizumab in patients with PDL1 positive ovarian cancer; *Gynecol Oncol*. **2019** Feb;152(2):243-250.
- 61) Fang F, Cardenas H, Huang H, Liu Y, Jiang G, Perkins S, Nephew KP, **Matei D**.: Genomic and Epigenomic Signatures of Platinum Re-sensitization in Ovarian Cancer, *Cancer Research*, 2018 Feb 1;78(3):631-644.
- 62) Wang J, Thomas M, Lin P, Cheng JX, **Matei DE**, Wei A.; siRNA Delivery Using Dithiocarbamate-Anchored Oligonucleotides in Gold Nanorods; *Bioconjug Chem*. **2019** Feb 20;30(2):443-453
- 63) Wang Y, Zong X, Mitra S, Mitra AK, **Matei D**, Nephew KP. IL6 mediates platinum-induced enrichment of ovarian cancer stem cells, *JCI Insight*. 2018 Dec 6;3(23):e122360. doi: 10.1172/jci.insight.122360.PMID: 30518684
- 64) Nieves-Neira W, Kim JJ, **Matei D**; Hormonal Strategies in Gynecologic Cancer: Bridging biology and therapy; *Gynecologic Oncology* 2018, Aug;150(2):207-210
- 65) Condello S, Sima LE, Ivan C, Cardenas H, Schiltz GE, Mishra RK, **Matei D**; Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche, *Cancer Research*, 2018, Jun 1;78(11):2990-3001.
- 66) **Matei D**, Ghamande S, Roman L, Secord AA, Nemunaitis J, Markham MJ, Nephew K, Jueliger S, Ogenesian A, Naim S, Su X, Keer H, Azab M, and Fleming G; A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses. *Clinical Cancer Research*, 2018; May 15;24(10):2285-2293.
- 67) Özeş AR, Pulliam N, Ertosun MG, Yılmaz Ö, Tang J, Çopuroğlu E, **Matei D**, Özeş ON, Nephew KP. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.; *Oncogene*. 2018 Mar 26
- 68) Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, **Matei D***, Ji-Xin Cheng*. Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells; *Cell Stem Cell*, 2017 Mar 2;20(3):303-314. * **Co-corresponding author**
Highlighted in Cell Stem Cell Editorial, Feinberg News, Purdue News
- 69) Condello S, Nwani NG, **Matei D**; The hunt for elusive cancer stem cells, *Oncotarget*, 2017 June 13 *(24) 38076-38077
- 70) Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, **Matei D**, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J.; Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy; *Br J Cancer*. 2018 Oct;119(9):1075-1085.
- 71) Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, **Matei D**, Nakshatri H, Rassool FV, Miller KD, Nephew KP.; An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.; *Clin Cancer Res*. **2018** Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204.

- 72) Sun H, Merrill D, An R, Turek J, **Matei D**, Nolte DD.; Biodynamic imaging for phenotyping profiling of 3D tissue culture; *J Biomed Opt.* 2017 Jan 1;22(1):16007
- 73) Miller DF, Yan P, Fang F, Buechlein A, Kroll K, Frankhouser D, Stump C, Stump P, Ford JB, Tang H, Michaels S, **Matei D**, Huang TH, Chien J, Liu Y, Rusch DB, Nephew KP.; Complete Transcriptome RNA-Seq, *Methods Mol Biol.* 2017;1513:141-162. doi: 10.1007/978-1-4939-6539-7_10.PMID: 27807835
- 74) Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, **Matei D**, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer; *Br J Cancer.* 2016 Nov 22;115(11):1313-1320.
- 75) Lee J, Yakubov B, Ivan C, Jones DR, Caperell-Grant A, Fishel M, Cardenas H, **Matei D**. Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.; *Neoplasia.* 2016 Oct 25;18(11):689-698.
- 76) Merrill D, An R, Sun H, Yakubov B, **Matei D**, Turek J, Nolte D. Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts. *Sci Rep.* 2016 Jan 6;6:18821. doi: 10.1038/srep18821
- 77) Cardenas H, Zhao J, Vieth E, Nephew KP, **Matei D**. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.; *Oncotarget.* 2016 Aug 22.
- 78) De Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, Nephew K, **Matei D**. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.; *Gynecol Oncol.* 2016 Sep;142(3):539-47.
- 79) Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, **Matei D**, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.; *Lancet Oncol.* 2016 Sep 8. pii: S1470-2045(16)30376-X.
- 80) Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, **Matei D**, Huang T, Nephew KP; NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.; *Oncogene.* 2016 Apr 4. doi: 10.1038/onc.2016.75.
- 81) Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, **Matei D**, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA.; Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy., *Cancer*, 2016 Jun 15;122(12):1844-52.
- 82) Lee CW, Guo L, **Matei D**, Stantz K.; Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts.; *J Biotechnol Biomater.* 2015 Sep;5(3).
- 83) Benson EA, Skaar TC, Liu Y, Nephew KP, **Matei D**.; Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.; *PLoS One.* 2015 Oct 20;10(10):e0141279.
- 84) Chun-Li Chang, Wanfeng Huang, Shadia Jalal, Bin-Da Chan, Aamer Mahmood, Safi Shahda, O'Neil BH, **Matei D** and Savran C; Circulating tumor cell detection using a parallel flow micro-aperture chip system; *Lab Chip*, 2015, Mar 17;15(7):1677-88
- 85) Huang W, Chang CL, Chan BD, Jalal SI, **Matei DE**, Low PS, Savran CA. Concurrent Detection of Cellular and Molecular Cancer Markers Using and Immunomagnetic Flow System; *Anal Chem.* 2015 Oct 20;87(20):10205-12. doi: 10.1021/acs.analchem.5b02215. Epub 2015 Jul 24.PMID: 26165381
- 86) Mitra A, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, Emerson RE, Cowden Dahl KD, Barbolina M, Nephew

- KP*, **Matei D***, Burdette JE*.: In vivo tumor growth of high-grade serous ovarian cancer cell lines, *Gynecology Oncology*, 2015, ug;138(2):372-7. ; **Co-corresponding**
- 87) Lee J, Condello S, Yakubov B, Emerson R, Caperele-Grant A, Hitomi K, Xie J, **Matei D.**; Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression; *Clin Cancer Research*, 2015, 2015 Oct 1;21(19):4482-93
 - 88) Meyer LA, Bohlke K, Powell MA, Fader AN, Franklin GE, Lee LJ, **Matei D**, Coallier L, and Wright AA; Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline: *JCO*, 2015, Sep 10;33(26):2908-13
 - 89) Ammakkanavar NR, **Matei D**, Abonour R, Einhorn LH.; High-Dose Chemotherapy for Recurrent Ovarian Germ Cell Tumors.; *J Clin Oncol*, 2015 Jan 10;33(2):226-7
 - 90) Tang J, Fang F, Miller DF, Pilrose JM, **Matei D**, Huang TH, Nephew KP; Global DNA methylation profiling technologies and the ovarian cancer methylome; *Methods Mol Biol.* 2015;1238:653-75.
 - 91) Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, Pilrose J, Choy G, Azab M, Pawelczak KS, VanderVere-Carozza P, Wagner M, Lyons J, **Matei D***, John J. Turchi*, and KP. Nephew*: The novel, small molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer; *Clinical Cancer Research*, 2014 Dec 15;20(24):6504-16, **Co-corresponding author**
 - 92) Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, and **Matei D*** TGF- β Induces Global Changes in DNA Methylation During the Epithelial-to-Mesenchymal Transition in Ovarian Cancer Cells; *Epigenetics*, 2014, 9(11):1461-72.
 - 93) Gordon MS, Robert F, **Matei D**, Mendelson DS, Goldman JW, Chiorean EG, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP, Rosen LS. An Open Label Phase 1b Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer. *Clin Cancer Res.* 2014 Dec 1;20(23):5918-26
 - 94) Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, Liu Y, Nephew KP, **Matei D**; Epigenetic Targeting of Ovarian Cancer Stem Cells; *Cancer Res.* 2014 Sep 1;74(17):4922-36. doi: 10.1158/0008-5472.CAN-14-1022. Epub 2014 Jul 17.
 - 95) Chan JK, Kiet TK, Blansit K, Ramasubbaiah R, Hilton JF, Kapp DS, **Matei D**. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. *Gynecol Oncol.* 2014 Jun;133(3):568-74. PMID: 24680769
 - 96) Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M, Wulfridge P, **Matei D***, Nephew KP; Decitabine reactivated pathways in platinum resistant ovarian cancer, *Oncotarget* 2014, Jun 15;5(11):3579-89. (**co-corresponding author**)
 - 97) Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, **Matei D**, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a *BRCA* mutation, *Lancet Oncology*, 2014 Jul;15(8):852-61.
 - 98) Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, and **Matei D**: Beta-Catenin Regulated ALDH1A1 is a Target in Ovarian Cancer Spheroids, *Oncogene*, 2014, Jun 23. doi: 10.1038/onc.2014.178.
 - 99) DeLeon M, N Akammannakuvar, **Matei D**; Adjuvant Therapy for Endometrial Cancer, *Journal of Gynecology Oncology*, 2014, Apr;25(2):136-47. doi: 10.3802/jgo.2014.25.2.136. Epub 2014 Apr 9. Review
 - 100) Yakubov B, Chen L, Belkin AM, Zhang S, Chelladurai B, Zhang ZY, **Matei D.**; Small Molecule Inhibitors Target the Tissue Transglutaminase and Fibronectin Interaction PLOs *One*, 2014 Feb 20;9(2)
 - 101) Rosen LS, Gordon MS, Robert F, **Matei D**; Endoglin for targeted cancer treatment; *Curr Oncol Rep.* 2014 Feb;16(2):365.

- 102) Lengyel E, Burdette JE, Kenny HA, **Matei D**, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS.; Epithelial ovarian cancer experimental models.; *Oncogene*. 2014 Jul 10;33(28):3619-33.
- 103) Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway R, Braly P, **Matei D**, Morosky A, Dodium PF, Einstein MH, Haluska F.; Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.; *Br J Cancer*. 2013 Mar 19;108(5):1021-6.
- 104) **Matei D**, Brown J, Frazier L.; Updates in the management of ovarian germ cell tumors. *Am Soc Clin Oncol Educ Book*. 2013:210-6
- 105) Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, **Matei D**, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR.; Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study. *Cancer*. 2014 Feb 1;120(3):335-43.
- 106) Condello S, Cao L, **Matei D**: Tissue Transglutaminase Regulates β -Catenin Signaling Through a c-Src Dependent Mechanism, *FASEB Journal*, 2013, Aug;27(8):3100-12
- 107) *Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, **Matei D**: Extracellular Tissue Transglutaminase Activates Non-canonical NF- κ B Signaling and Promotes Metastasis in Ovarian Cancer, *Neoplasia*, 2013, June 15 (6), 609-19 (corresponding author)
- 108) An R, Tureck J, **Matei. D**, Nolte, D; Live Tissue Viability and Chemosensitivity Assays Using Digital Holographic Motility Contrast Imaging; *Applied Optics*, Vol. 52, Issue 1, pp. A300-A309 (2013)
- 109) **Matei D**, Brown J, Frazier L. Updates in the management of ovarian germ cell tumors, *Am Soc Clin Oncol Educ Book*. 2013. doi: 10.14694/EdBook_AM.2013.33.e210.PMID: 23714505
- 110) Shao M, Hollar S, Chambliss D, Schmitt J, Emerson R, Chelladurai B, Perkins S, Ivan M, and Matei D; Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer, *Molecular Cancer therapeutics, Molecular Cancer Ther*. 2012 Jul;11(7):1576-86.
- 111) Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, **Matei D**, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer.; *N Engl J Med*. 2012 Apr 12;366(15):1382-92. Epub 2012 Mar 27
- 112) Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, **Matei D**, Behbakht K, Grothusen J, Fleming G, Lee NK, Arnott J, Bray MR, Fletcher G, Brokx RD, Castonguay V, Mackay H, Sidor CF, Oza AM; ENMD-2076, An Oral Inhibitor of Angiogenic and Proliferation Kinases, has Activity in Recurrent, Platinum Resistant Ovarian Cancer; *Eur J Cancer*. 2012 Aug 21.
- 113) Alley WR Jr, Vasseur JA, Goetz JA, Svoboda M, Mann BF, **Matei D**, Menning N, Hussein A, Mechref Y, Novotny MV; N-linked Glycan Structures and Their Expressions Change in the Blood Sera of Ovarian Cancer Patients; *J Proteome Res*. 2012 Apr 6;11(4):2282-300
- 114) **Matei D**^{**}, Fang F[#], Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang TH, Nephew KP* Epigenetic Resensitization to Platinum in Ovarian Cancer; *Cancer Res*, 2012 May 1;72(9):2197-205 (*corresponding authors, # equal contribution)
- 115) Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, **Matei D**.; Sorafenib in Combination with Weekly Topotecan in Recurrent Ovarian Cancer, A Phase I/II Study of the Hoosier Oncology Group; *Gynecol Oncol*. 2011 Dec;12(3):499-504
- 116) Cao L, Shao M, **Matei D***: Tissue Transglutaminase Links TGF- β , Epithelial to Mesenchymal Transition, and a Stem Cell Phenotype in Ovarian Cancer, *Oncogene* 2012, May 17;31(20):2521-34

- 117) Khanna M., Chelladurai B., Shao M., **Matei D***, Meroueh S: Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase, *Molecular Cancer Therapeutics*, 2011, Apr;10(4):626-36, co-corresponding author.
- 118) Shao M, Rossi S, Chelladurai B, Shimizu M, Ntukogu O, Ivan M, Calin GA, **Matei D**: PDGF Induced MicroRNA Alterations in Cancer Cells; *Nucleic Acid Research*, 2011, May;39(10):4035-4
- 119) Schmitt, J and **Matei, D**: Targeting Angiogenesis in Ovarian Cancer. *Cancer Treat Rev.*; 2012 Jun; 38(4):272-83. Epub 2011 Jul 18
- 120) **Matei D**, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ., Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Gynecologic Oncology Group Trial; *Journal of Clinical Oncology* 2011 Jan 1;29(1):69-75
- 121) Ivan M, **Matei D**: Blockade of FGF Signaling: Therapeutic Promise for Ovarian Cancer, *Cancer Biol Ther.* 2010 Sep;10(5):505-8
- 122) Balch C, **Matei DE**, Huang TH, Nephew KP. Role of Epigenomics in endometrial and ovarian cancers, *Epigenomics*. 2010 Jun;2(3):419-47. doi: 10.2217/epi.10.19. PMID: 22121902
- 123) Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, **Matei D.**: Continued Chemotherapy after Complete Response to Primary Therapy Among Women with Advanced Ovarian Cancer: A Meta-Analysis. *Cancer*. 2010 Nov 15;116 (22):5251-60.
- 124) Fang F, Balch C, Schilder S, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, **Matei D**. A Phase I and Pharmacodynamic Study of Decitabine in Combination with Carboplatin in Patients with Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer. *Cancer*, 2010 Sep 1;116(17):4043-53,
- 125) **Matei D**, Nephew KP: Epigenetic Therapies for Chemoresensitization of Epithelial Ovarian Cancer. *Gynecol Oncol*. 2010 Feb;116(2):195-201. *co-corresponding author
- 126) De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, **Matei D**, Muller CY, Richards WE: Phase II Clinical Trial of Ixabepilone in Patients with Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Vancer: A Gynecologic Oncology Group Study. *Journal of Clinical Oncology* 2010 Jan 1;28(1):149-53.
- 127) Shao M, Cao L, Shen C, Satpathy M, Chelladurai B, Bigsby RM, Nakshatri H, **Matei D**: Epithelial-to-Mesenchymal Transition and Ovarian Tumor Progression Induced by Tissue Transglutaminase. *Cancer Research*. 2009 Dec 15;69(24):9192-201. corresponding author; **Selected for Faculty 1000.**
- 128) Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, **Matei D**, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S; ASSIST-1 Study Group.: Phase 3 Randomised Study of Canfosamide (Telcyta((R)), TLK286) Versus Pegylated Liposomal Doxorubicin or Topotecan as Third-line Therapy in Patients with Platinum-Refractory or -Resistant Ovarian Cancer, *European Journal of Cancer*, 2009, Sep;45(13):2324-32.
- 129) Balch C, Fang F, **Matei D**, Huang TH, Nephew KP: Epigenetic Changes in Ovarian Cancer, *Endocrinology*, 2009, Sep;150(9):4003-11.
- 130) **Matei D**, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C.: Activity of 2 methoxyestradiol (Panzem((R)) NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Hoosier Oncology Group Trial. *Gynecology Oncology*, 2009, Oct;115(1):90-6; corresponding author
- 131) Satpathy M, Shao M, Emerson R, Donner DB, **Matei D**: Tissue Transglutaminase Regulates MMP-2 in Ovarian Cancer by Modulating CREB Activity, *J Biol Chem*. 2009 Jun 5;284(23):15390-9.
- 132) **Matei D***, Miller AMS, Monahan P, Gershenson D, Zhao Q, Cella D, Champion VL, Williams SD; Chronic Physical Effects and Health Care Utilization In Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study, *Journal of Clinical Oncology*, 2009 Sep 1;27(25):4142-9. * corresponding author

- 133) Zhang S, Balch C, Chan M, Lai HC, **Matei D**, Nephew K: Identification and Characterization of Ovarian Cancer Initiating Cells from Human Ovarian Tumors, *Cancer Research*, 2008 Jun 1; 68(11):4311-20.
- 134) Kimball K. J., Numnum T. M., Estes J M, Kirby T O, Koch KM, Zamboni W C, Barnes M N, **Matei D.**, Alavarez R. D.; A Phase I Study Of Lapatinib In Combination with Carboplatin In Women with Platinum Sensitive Recurrent Ovarian Carcinoma, *Gynecology Oncology*, 2008 Oct;111(1):95-101.
- 135) Schmitt J and **Matei D**: PDGFR Inhibitors in Ovarian Cancer, *Clinical Ovarian Cancer*, 2008, (1), 120-126.
- 136) Cao L, Petrusca D, Satpathy M, Nakshatri H, Petrache I, **Matei D**; Tissue Transglutaminase Protects Epithelial Ovarian Cancer Cells from Cisplatin Induced Apoptosis by Promoting Cell Survival Signaling, *Carcinogenesis*, 2008 Oct;29(10):1893-900.
- 137) **Matei D**, Emerson RE, Schilder J, Menning N, Baldrige LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G.. Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial. *Cancer*, 2008 Aug 15;113(4):723-32.
- 138) **Matei D**, Kellich S, Cao L, Menning N, Emerson R, Sledge G: PDGF BB Induces VEGF Secretion in Ovarian Cancer, *Cancer Biology and Therapy*, 2007 Dec;6(12):1951-9.
- 139) Strother R and **Matei D**: Pegylated Doxorubicin in Ovarian Cancer. *Therapeutics and Clinical Risk Management*. 2009 Jun;5(3):639-50.
- 140) Suresh G, Badve S and **Matei D**: Breast Mass in a Patient with Ovarian Cancer, *Journal of Reproductive Medicine*, 2009; 54:639-644.
- 141) **Matei D**. Novel Agents in Ovarian Cancer, Review; *Expert Opin Investig Drugs*. 2007 Aug;16(8):1227-1239.
- 142) Satpathy M, Cao, Pincheira R, Emerson R, Nakshatri H, **Matei D**: Tissue Transglutaminase Enhances Peritoneal Ovarian Tumor Dissemination by Stabilizing $\beta 1$ Integrin", *Cancer Research*, Aug 1 2007;67(15):7194-20.
- 143) **Matei D**, Satpathy M, Cao L, Lai YC, Nakshatri H, Donner DB.: The Platelet-Derived Growth Factor Receptor Alpha is Destabilized by Geldanamycins in Cancer Cells, *J Biol Chem*. 2007 Jan 5;282(1):445-53.
- 144) Gordon M, **Matei D**, Aghajanian C, Karlan BY; Clinical Activity of Pertuzumab (rhuMAb 2C4), A HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship with Tumor HER2 Activation Status, *Journal of Clinical Oncology*, 2006 Sep 10;24(26):4324-32.
- 145) **Matei D**, Emerson R, Lai YC, Baldrige LA, Rao J, Yiannoutsos C, Donner D.: Autocrine Activation of PDGFR α Promotes the Progression of Ovarian Cancer, *Oncogene*, Dec. 12, 1-10, 2005.
- 146) Chan M, Wei S, Wen P, Wang Z, **Matei D**, Liu, J, Liyanarachchi, S., Brown, R., Nephew, KP, Yan, PS, TH Huang: Hypermethylation of 18S and 28S Ribosomal DNAs Predicts for Progression Free Survival in Patients with Ovarian Cancer, *Clinical Cancer Research*, 2005 Oct 15; 11(20):7376-83.
- 147) **Matei D**, Chang DD and Jeng MH. Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth Through a Mechanism Dependent on PDGFR and Akt Inactivation, *Clinical Cancer Research*, 2004, 10 (2), 681-90.
- 148) **Matei D**, Graeber TG, Baldwin RL, Karlan BY, Rao J and Chang DD. Gene Expression in Epithelial Ovarian Carcinoma; *Oncogene*, 2002, 21(41):6289-98.
- 149) Gillan L, **Matei D**, Fishman D, Gerbin S and Chang DD. Periostin Secreted by Ovarian Epithelial Carcinoma is a Ligand for the Integrin $\alpha V\beta 3$ and $\alpha V\beta 5$ and Promotes Motility of Ovarian Epithelial Cells, *Cancer Research*, 2002, 62(18):5358-64.
- 150) **Matei D**, Brenner B, Marder VJ. Acquired Thrombophilic Syndromes, *Blood Reviews*, 2001, 15, 31-48

- 151) Madajewicz S, **Matei D**, Hentchel P, Kudelka A et al. Actual 5-Year Survival of Patients with Stage III B Breast Carcinoma: Phase II Trial of Methotrexate, Vinblastine, Adriamycin, Cisplatin and Folinic Acid; *Journal of Cancer Investigation*: 1999; 17(7):463-7.
- 152) Roy R, **Matei D** and Kauffman LD. Emphysematous Septic Arthritis Due to E. Coli, Case Report and Review of the Literature, *The Journal of Rheumatology*, 1995; 22:9:1776-8.
- 153) **Matei D**, Madajewicz S, Chowan N, Hagag N, et al. Preclinical and Clinical Evaluation of 5-Fluorouracil Biochemical Modulation with Folinic Acid and Hydroxyurea for Patients with Colorectal Carcinoma, *Cancer*, 1995, 76 (8): 1130-5.

Non-refereed (Chapters and Reviews)

1. **Matei D**, Robert Emerson, Jubilee Brown: Ovarian Germ Cell Tumors, Principles and Practice of Gynecologic Oncology, Sixth Edition by Lippincott, Williams & Wilkins. 2017,
2. **Matei D**, Frazier LA, Hurteau JA, Panshakar FD: Germ cell tumors of the ovary, Textbook of Uncommon Cancers, Fifth Edition by Derek Raghavan, Wiley Medical Publications, 2016.
3. Jessica Thomes Pepin, Horacio Cardenas, Kenneth P. Nephew, **Daniela Matei**; Chapter 3: Epigenetics; *Translational Advances in Gynecologic Cancers*; pages 35-58, First Edition by Michael Birrer, Elsevier Inc, 2017
4. Y Wang, F Fang, S Condello, **D Matei**, K Nephew: Cancer Stem Cells as New Therapeutics Targets for Ovarian Cancer, *Cancer Stem Cells*, First Edition, Edited by Huiping Liu and Justin Lathia, by Elsevier, 2016
5. **Matei D**, Michael H, Gershenson DM: Ovarian Germ Cell Tumors, Principles and Practice of Gynecologic Oncology, Fifth Edition by Lippincott, Williams & Wilkins. 2013,
6. **Matei D**, Michael H and Schilder J: Germ cell tumors of the Ovary, Textbook of Uncommon Cancers, Fourth Edition by Derek Raghavan, Wiley Medical Publications, 2011.
7. **Matei D**, Michael H, Gershenson DM, Russel A: Ovarian Germ Cell Tumors, Principles and Practice of Gynecologic Oncology, Fifth Edition by Lippincott, Williams & Wilkins. 2009,
8. **Matei D**, Michael H, Schilder J: Germ cell tumors of the Ovary, Textbook of Uncommon Cancer, Third Edition by Derek Raghavan, Wiley Medical Publications, 2006.
9. **Matei D**. Critical Commentary: Neuroprotective Effects of Vitamin E; *The Women's Oncology Review*, 4 (4), 2006
10. **Matei D** Gershenson DM, Russel A, Silva E: Ovarian Germ Cell Tumors, Principles and Practice of Gynecologic Oncology, Fourth Edition by Lippincott, Williams & Wilkins. 2005, 989-1011.
11. **Matei D**. Patients With Platinum Sensitive Recurrent Ovarian Cancer Should NOT Receive Carboplatin and Paclitaxel". *Controversies in Gynecologic Malignancies*, a Gynecologic Oncology Group Symposium, 2004.
12. **Matei D**. Critical Commentary: Phase III Trial Of Doxorubicin Plus Cisplatin With Or Without Paclitaxel Plus Filgrastim In Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study, *The Women's Oncology Review*, 4 (4), 2004, 287-289.
13. **Matei D** and Schiller G: Autoimmune Thrombocytopenias, *Proceedings of UCLA Healthcare*, 2002, 6 (1): 33-39.
14. Marder VJ and **Matei D**: Hereditary and Acquired Thrombophilic Syndromes, Hemostasis and Thrombosis, Fourth Edition, 2001 by Lippincott Williams & Wilkins, 1243-1275.

OTHER PUBLICATIONS:

1. **Matei Daniela**, "Bloom", *Ann Intern Med*. 2012 Aug 21;157(4):297.
2. **Matei Daniela**: "The Wayback Machine", Poetry, Art Publishing House, Bucharest, Romania, 2011 Nominated for Best Debut Book of 2011 by the Romanian Writers Association
3. **Matei Daniela**: " Nest in the City", Poetry—Driftwood Press, 2017

III) GRANTS/ RESEARCH SUPPORT:

ACTIVE RESEARCH GRANTS

U54CA268084 (Backman, Matei, Zhang MPI) **12/1/2021-11/30/2026**
NIH/NCI

Northwestern University Center for Chromatin Nanoimaging in Cancer (NU-CCNIC)

The goal of this project is to provide an epigenomic map of chromatin in cancer stem cells by using chromatin imaging and advanced sequencing technologies.

Role: MPI (PI of Research TestBed Unit)

Total Award Amount (including Indirect Costs): \$5,187,505

BX11051359 (Matei PI) **07/01/2025-09/30/2033**

US Department of Veterans Administration

Targeting Unfolded Protein Response in Ovarian Cancer

Senior Clinician Investigator Award

The goal of this grant is to examine and target UPR mechanisms in platinum resistant ovarian cancer models.

Role: PI

Total Award Amount (including Indirect Costs): \$1,370,000

BX006012 **07/01/2022-06/30/2026**

US Department of Veterans Administration (Matei PI)

Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer

The goal of this grant is to examine lipid metabolism in platinum resistant ovarian cancer models and human specimens.

Role: PI

Total Award Amount (including Indirect Costs): \$1,200,000

Department of Defense

Investigator Initiated Award (Schiltz/Matei MPI)

06/01/22 - 05/31/25--NCE

PROTACS Targeting Tissue Transglutaminase in Ovarian Cancer

This proposal will develop PROTACS to degrade TG2 in preclinical models of ovarian cancer.

Role: MPI

Total Award Amount (including Indirect Costs): \$1,200,000

Department of Defense

Investigator Initiated Award (Matei /Zhang MPI)

09/01/23 - 08/31/26

Targeting Tissue Transglutaminase To Enhance Anti-tumor Immunity in Ovarian Cancer

The goal of this project is to mechanistically dissect how the protein TG2 alter anti-tumor immunity and to develop TG2 inhibitors for clinical use along with immunotherapy.

Role: MPI

Total Award Amount (including Indirect Costs): \$1,200,000

NIH-R01 EB032391-01 (PI: Ji-Xin Cheng)

04/01/2022-12/31/2025

High-content High-speed Chemical Imaging of Metabolic Reprogramming by Integration of Advanced Instrumentation and Data Science

The goal of this project is to develop two complementary platforms that will allow high-speed, high-content, and high-sensitivity mapping of cell metabolism.

Role: Co-I (Cheng, PI)

Total Award Amount (including Indirect Costs): \$334,382

Ovarian Cancer Research Alliance

Junzui Li; post doctoral fellowship

1/1/2025-12/31/2026

The role of the CD74 receptor in ovarian cancer

Role: Mentor

Total Award Amount (including Indirect Costs); \$100,000

Ovarian Cancer Research Alliance of Cincinnati

07/28/2023-07/27/2025

Targeting Pyrimidine Synthesis to Overcome Resistance to Platinum in Ovarian Cancer

The goal of this project is to determine whether platinum-resistant ovarian cancer cells and tumors are dependent on the de novo pyrimidine synthesis pathway.

Role: PI

Total Award Amount (including Indirect Costs); \$100,000

NIH/NCI

CA267544 (Adli, PI)

09/2022-08/2027

Chemo-mediated transcriptional reprogramming in ovarian cancer

The goal of provide new mechanistic insight into the role of key transcription factor network that govern platinum resistance in ovarian cancer.

Role: co-investigator

NIH/NCI

UG1CA233320 (Benson/Matei MPI)

04/01/2019 – 09/28/2025

Northwestern University Lead Academic Participating Site (NCI National Clinical Trials Network)

The goal of this grant is to allow the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) to continue leadership of and participation in Network Group trials as a high performing LAPS. This grant will enable expanded participation of LCC members in NCTN trials, scientific leadership of key network activities, and access to unique scientific resources to advance cancer interventions.

Role: MPI

Total budget (including indirect cost: \$3,960,956)

P30CA060553

08/10/18 - 07/31/25--renewed

The Robert H. Lurie Comprehensive Cancer Center

Role: Program Leader, Translational Research in Malignancy

Cancer Center Support Grant

The major goal of this project is to establish an NCI designated Cancer Center by facilitating cancer research, education, patient care, and cancer control and prevention to accomplish its mission of reducing the incidence, morbidity, and mortality of cancer.

Role: Co-I, TRIM Program Leader

Total budget (including indirect costs): \$30,151,415

Pending Research Grants:

NIH/NCI

01/2026-12/2030

Role: MPI (contact PI)

Lipid Unsaturation Drives Ovarian Cancer Progression:

under review (previously 20th percentile)

The goals of this application are to determine single-cell-level SCD activity by mid-infrared photothermal (MIP) imaging and demonstrate that elevated SCD activity is a cellular response to oxidative stress; to demonstrate how the balance between UFAs and SFAs regulated by SCD promotes metastatic dissemination and to investigate how SCD modulates anti-tumor immune responses in the tumor microenvironment.

NIH/NCI

01/2026-12/2030

Role: PI

FTO Regulated m6A Modifications in High Grade Serous Ovarian Cancer

under review (previously 25th percentile)

We propose three main objectives: 1) to demonstrate that FTO inhibits the tumorigenic properties of FTE cells; 2) to identify and mechanistically characterize FTO gene targets involved in tumor initiation focusing on effects of FTO on stemness promoting pathways in the fallopian tube cells, and 3) to determine key repressor mechanisms for FTO in HGSOV.

NIH/NCI

UG1CA233320 (Benson/Matei MPI)

03//2026 – 02/2032

Northwestern University Lead Academic Participating Site (NCI National Clinical Trials Network)

Under review

The goal of this grant is to allow the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) to continue leadership of and participation in Network Group trials as a high performing LAPS. This grant will enable expanded participation of LCC members in NCTN trials, scientific leadership of key network activities, and access to unique scientific resources to advance cancer interventions.

Role: MPI

Total budget (including indirect cost: \$8,957,724)

P30CA060553

08/2025 - 07/2030

Impact Score 1

The Robert H. Lurie Comprehensive Cancer Center

Role: Program Leader, Translational Research in Malignancy

Cancer Center Support Grant

The major goal of this project is to establish an NCI designated Cancer Center by facilitating cancer research, education, patient care, and cancer control and prevention to accomplish its mission of reducing the incidence, morbidity, and mortality of cancer.

Role: Co-I,

TRIM Program Leader

Total budget (including indirect costs): \$36,932,620

Mentees' Awards--completed

Department of Defense; Condello PI 8/2019-7/2023
Investigating and Targeting Ovarian Cancer Stem Cells Interactions with the Tumor Niche
Role: Mentor; 3% effort

Gynecologic Oncology Foundation; Barber PI 7/2019-6/2024
Improving Surgical Outcomes in Ovarian Cancer
Role: Mentor; 10% effort

Bristol Myers Squibb Foundation; Diversity in Clinical Trials; Roque PI# 9/2021-9/2023
Career Development Program
Role: Mentor, 3% effort

Ovarian Cancer Research Alliance, Valdivia PI#
Complement Activation at the Interface between adipocyte and ovarian cancer cells 3/2023-3/2024
postdoctoral fellowship
Role: Mentor

Friends of Prentice; Roque, PI#
The Effects of Cisplatin Based Heated Intra-Peritoneal Chemotherapy (HIPEC) on Ovarian Cancer
DNA Damage & Repair: Exploring new markers to predict platinum free interval 07/2022-06/2024
Role: Co-I, mentor

Ovarian Cancer Research Foundation, Wang: PI
Epigenetic Targeting of Ovarian Cancer Stem Cells—postdoctoral fellowship 1/2018-1/2019
Role: Mentor

Lurie Cancer Center: Translational Bridge Award (H. Huang) 10/2018-10/2019
The role of FTO in Ovarian Cancer Stem Cells
Role: Mentor

URM

COMPLETED RESEARCH GRANTS

R01 CA224275 (Matei contact PI) 07/2018-07/2024

Targeting lipid unsaturation in ovarian cancer stem cells

The major goal is to describe the function of unsaturated fatty acids in cancer stem cells and chemo-resistant ovarian cancer models.

Role: Matei MPI

Total Award Amount (including Indirect Costs): \$2,883,447

Department of Defense

Investigator Initiated Award (Matei PI) 05/01/21 - 04/30/25

Targeting Cholesterol Metabolism in Platinum Resistant Ovarian Cancer

This proposal will study how cholesterol metabolism contributes to platinum resistance in ovarian cancer and targeting using HDL based nanoparticles.

Role: PI

Total Award Amount (including Indirect Costs): \$960,000

NCI P20 CA233304-01A1 (Simon PI)

9/1/2020-8/31/2025 NCE

The Northwestern University Cancer Health Equity Research SPORE (NU-CHERS); Simon PI

The major role of this project is to understand molecular based disparities in gynecologic cancers to provide an improved prevention, early detection, and treatment for such cancers.

Role: Matei, PI of Project 2; co-PI of Administrative Core

Total Award Amount (including Indirect Costs): \$2,993,413

Department of Defense

Clinical Translational Award

07/01/21 - 05/30/25

Blood-Based DNA Methylation Biomarkers of Acquired Platinum Resistance in Women with Ovarian Cancer

The overall goal of this proposal is to develop new blood-based biomarkers to identify patients that are most likely to benefit from hypomethylating drugs.

Role: co- I (Nephew PI)

Total Award Amount (including Indirect Costs): \$185,874

I01BX000792

10/1/2019-9/30/2024

US Department of Veterans Administration (Matei PI)

New Epigenetic Targets in Ovarian Cancer Stem Cells

The goal of this grant is to examine the function of H3K79 methylation in ovarian cancer stem cells.

Role: PI

Total Award Amount (including Indirect Costs): \$710,000

R01 CA182832- (Matei contact PI)

02/01/14-01/31/20

An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

The goal of this proposal is to test the effects of a hypomethylating strategy on the ovarian cancer methylome in the setting of an ongoing therapeutic clinical trial with correlative studies by using state-of-the-art massive parallel sequencing and bioinformatics approaches.

Role: co-PI

Friends of Prentice

10/1/19-8/31/2022

The role of FTO in DNA Repair in Ovarian Cancer

This project will evaluate the role of RNA methylation in DNA repair in ovarian cancer.

Role: PI

Total budget (including indirect costs) \$100,000

PinotBio

NTX3 a new hypomethylating drug for ovarian cancer

5/1/2021-5/1/2023

This project will evaluate the effects of NTX3 in preclinical models of ovarian cancer.

Role:PI

Total budget (including indirect costs) \$140,632

W81XWH170141-NCE

Department of Defense; Matei Daniela (PI)

04/01/2017-04/31/2021

Epigenomic Priming to Enhance Immunotherapy in Ovarian Cancer

This project will test the hypothesis that priming with a DNA methylation inhibitor will enhance effects of immune checkpoints inhibitors in patients with platinum resistant ovarian cancer. Tumor tissue from patients treated with this regimen will be used for immunologic assays and genomic characterization.

Role: PI

BX000792-06 Matei, Daniela E (PI) NCE

10/01/10-12/31/19

US Department of Veterans Administration

The Tissue Transglutaminase-Fibronectin Interaction in Ovarian Cancer Metastasis

The goal of this project is to elucidate the mechanism by which TG2/FN complex initiates oncogenic signaling leading to metastasis and to characterize pre-clinically new hits identified during the screening process.

Role: PI

Ovarian Cancer Research Fund Alliance (Nephew-contact PI)

01/01/2017-12/30/2019

Epigenetic Vulnerabilities of Ovarian Cancer Stem Cells

This collaborative project involving 4 PIs from Northwestern and Indiana University plans to identify how key pathways are epigenetically maintained and regulated in ovarian cancer stem cells. The four projects represent a united front for discovering epigenetic vulnerabilities in ovarian CSCs.

Role: co-PI

V-Foundation Matei (Contact PI)

12/01/13-12/30/17

An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer

This project will identify the critical events that govern the development of platinum resistance, which can then serve as predictive markers of response to epigenetic-targeting strategies.

Role: PI

R21 CA198409-02 (Hurley contact PI)

07/01/15-06/30/18

Targeting Ovarian Cancer Stem Cells Through Selective Inhibition of ALDH1A1

The goal of this project is to optimize and validate the lead inhibitor for the first time in a cancer model, focusing on inhibiting the functions of ALDH1A1+ ovarian CSCs.

Role: co-PI (10%)

R01 EB016582 (Nolte, David contact PI)

05/01/13-04/30/18

Tissue-dynamics Imaging for Therapeutic Efficacy in Ovarian Cancer

The goal of this project is to investigate tissue biodynamic imaging as a new method to predict chemosensitivity in ovarian cancer.

Role: co-PI (10%)

NCI R21 (Matei, PI; \$375,000)

9/2011-2/2015

Tissue Transglutaminase modulates tumor-stroma Interaction in pancreatic cancer

Objectives: This project will evaluate the effect of TG2 on stroma formation and resistance to gemcitabine in pancreatic tumors

Role: PI

US Department of Veterans Affairs VA Merit Award (Matei PI, \$600,000)

10/2010-9/2014

The Functional Role of TG2 in Ovarian Cancer

Role: PI

Ovarian Cancer Research Foundation: Program Project Planning Grant

(Matei co-PI; \$900,000)

1/2011-12/2013

Epigenetic Modulation of Platinum Activity in Ovarian Cancer

Role: Co-PI

American Cancer Society Research Scholar Award 118022

(Matei, PI; \$750,00)

1/2009-12/2013

Targeting the TG2/Fibronectin Interaction in Ovarian Cancer

Objectives: This project will perform high throughput screening for inhibitors of TG2-fibronectin.

Role: PI

NCI: P30 CA82709-09 (Loehrer, P. PI)

10/2009-8/20

Cancer Center Support Grant

Objectives: The major goal of this project is to establish an NCI designated Cancer Center by facilitating cancer research, education, patient care, and cancer control and prevention to accomplish its mission of reducing the incidence, morbidity, and mortality of cancer.

Role: co-I

American Cancer Society Mentored Research Scholar Grant (Matei, PI) 7/05-12/2009

The functional role of PDGFR α in Ovarian Carcinoma”

Objectives: This proposal will evaluate PDGF regulated signaling in ovarian carcinoma.

Role: PI

US Department of Veterans Affairs VA Merit Award (Matei PI, \$600,000) 1/2007-3/2010

The Functional Role of TG2 in Ovarian Cancer

Objectives: This project will evaluate the role of TG2 in the process of peritoneal metastasis.

Role: PI

National Cancer Institute CA133877 (Matei PI) 7/2008-6/2011

Decitabine Strategy for Restoring Carboplatin Sensitivity”

Objectives: This project will evaluate the role of decitabine in platinum resensitization in a clinical trial

(Role: PI)

National Cancer Institute: P50 (Huang/Nephew co-PIs) 12/01/04-12/20/2009

Epigenetic Changes in Cancer Genomes/Predicting Drug Resistance in Cancer Genomes

Objectives: This project will investigate the role of methylation in acquired drug resistance.

(Role: Co-I)

Walther Cancer Institute: (Matei, PI) 5/2011-5/2013

IU-Purdue Embedding Program

Objectives: To develop folate coated gold nanorods targeting TG2 in ovarian cancer.

To provide integrated training and mentoring for two fellows.

Role: PI

Walther Cancer Institute: (Matei, PI; \$50,000) 7/2011-7/2013

IU-Purdue Embedding Program

Objectives: To develop a new platform for detection of circulating tumor cells in cancer.

To provide integrated training and mentoring for two fellows.

Role: PI

Showalter Fund (Matei, PI; \$50,000). 7/2006-6/2007

TG2 Facilitates Intraperitoneal Spread of Ovarian Cancer

Role: PI

Amgen Oncology Institute (Matei, PI, \$180,000). 7/2004-6/2007

The Functional Role of PDGFR in Ovarian Cancer

Objectives: This proposal will evaluate PDGF regulated signaling in ovarian carcinoma

Role: PI

Marsha Rivkin Ovarian Cancer Fund (Matei PI, \$30,000) 7/2006-6/2007

The Functional Role of TG2 in Ovarian Cancer

Role: PI

Clarian Values Fund (Matei, PI; \$80,000) 5/04-4/06

Markers of Sensitivity To PDGFR Inhibition In Ovarian Carcinoma In-Vivo

Objectives: This proposal will evaluate translational end-points in human tumor specimens obtained as part of a clinical trial utilizing imatinib plus docetaxel in patients with refractory ovarian carcinoma.
Role: PI

IV) ADMINISTRATION/SERVICE/LEADERSHIP:

III A) NATIONAL

Organization	Activity	Dates
National Cancer Institute		
NCI-I Committee	Ad Hoc member	2011
NCI-I Committee (3 review sessions per year)	Chartered Member	2011-2015
NCI-A Committee	Ad Hoc Member	2012
NCI Taskforce Steering Committee	Member	2012-2015
Ovarian Cancer panel		
NCI-A Committee	Ad Hoc Member	2015
NCI-ZCA1-RTRB-E-O1	Ad hoc member	2015
NCI-ZCA1-RPRB-O-J5	Ad Hoc Member	2015
NCI-ZCA1-RTRB-E-J2	Ad Hoc Member	2015
NCI-J	Ad Hoc Member	2016
NCI-ZRG1-BST-A-55	Member	2016
NCI-ZCA1-RPRB-F-O1	Ad Hoc Member	2016
NCI-ZRG1-BMCT-C01	Ad Hoc Member	2016
NCI- ZCA1 TCRB-Q (J1)	Ad Hoc Member	2016
NCI-Cancer Genetics	Ad Hoc Member	2017
NCI-ZRG1-BMCT-C01	Ad Hoc Member	2017
NCI-CONC	Ad Hoc Member	2017
NCI-A RTRB	Ad Hoc Member	2017
NCI-CONC (3 sessions per year)	Chartered member	2018-2020
NCI-ZCA-RPRB-L01	Ad Hoc member	2018
NCI ZCA1-RPRB-F-02	Ad Hoc member	2018
NCI Intramural review panel	Member	2018
Women's malignancies branch		
NCI-ZRG1-OTC-H-13	Ad Hoc member	2019
NCI-CONC	Chair	2020-2022
NCI-MCTB	Ad hoc member	2024
American Society of Clinical Oncology		
ASCO Program Committee	Member	2011-2013
Gynecologic Oncology		
ASCO National Meeting		
Gynecologic Oncology Educational Session	Co-chair	2005
ASCO Gynecology Oncology Guidelines Committee	Member	2016-present
ASCO Taxonomy Committee	Member	2019-present
ASCO Question Writing Group	Member	2018-2019
ASCO Clinical Science Symposium	Co-Chair	2019
Gynecology Oncology Group		
Phase I Committee	Member	2006-2008
Developmental Therapeutics Committee	Member	2008-2015
Data Safety and Monitoring Board	Member	2011-2014
Safety Review Committee	Member	2011-2019
Committee on Experimental Medicine	Member	2011-present
Ovarian Cancer Committee	Member	2018-Present
Department of Defense		
Department of Defense Ovarian Cancer Research Program	Reviewer	2019
Ovarian Cancer Academy	Member	2019-2023
Department of Defense Ovarian Cancer Research Program	Chair	2024

National Comprehensive Cancer Network (NCCN)

NCCN Ovarian Cancer Panel	Member	2018-present
---------------------------	--------	--------------

US Department of Veterans Affairs

Oncology VA Committee, Oncology Study Section (2 review sections per year)	Member	2010-2014
---	--------	-----------

American Association for Cancer Research

AACR Program Committee	Member	2021
------------------------	--------	------

Society of Gynecologic Oncology

Program Committee	Member	2021
-------------------	--------	------

Forbeck Symposium

“Ovarian Cancer Challenges”	Co-Chair	2022
-----------------------------	----------	------

AACR Annual Meeting Oral Session

“Drug Resistance in Cancer”	Co-Chair	2023
-----------------------------	----------	------

ESMO Immunology Oral Session

Epigenetic Therapy	Co-Chair	2023
--------------------	----------	------

FEBS Conference on Tissue Transglutaminases

Organizing committee	2024
----------------------	------

Others:

The Women’s Oncology Review	Contributing Editor	2004-2008
-----------------------------	---------------------	-----------

National Institute of General Medical Sciences (NIGMS): Review Panel for Minority Biomedical Research Support (MBRS)	Ad Hoc Member	2007
--	---------------	------

Ovarian Cancer Research Fund (OCRF)	Reviewer	2008
-------------------------------------	----------	------

Marsha Rivkin Foundation	Reviewer	2024
--------------------------	----------	------

Manuscript reviewer for: Nature; New England Journal of Medicine; Journal of Clinical Investigation, Cancer Research (Journal of AACR); Nature Communications, Clinical Cancer Research (Journal of AACR); Lancet Oncology, Cancer Discovery, Lancet, Molecular Cancer, Molecular Cancer Therapeutics (Journal of AACR); Gynecologic Oncology (Journal of the Society of Gynecology Oncology); Proceedings of the National Academy of Sciences (PNAS); EMBO, Molecular Medicine; Oncology; Cancer (Journal of the American Cancer Society); Annals of Neurology; British Journal of Cancer; European Journal of Cancer; Molecular Cancer Research; European Journal of Pharmacology; Carcinogenesis; Journal of Clinical Oncology (Journal of ASCO); Annals of Internal Medicine (ACP Journal)

Editorial Boards

Journal of Epithelial Biology and Pharmacology	Member	2007-2010
--	--------	-----------

American Journal of Translational Research	Member	2010-2015
--	--------	-----------

Gynecology Oncology	Member	2013-2016
---------------------	--------	-----------

III B) INTERNATIONAL

Organization	Activity	Dates
Austrian Science Fund	Ad Hoc Grant Reviewer	2007
Austrian Science Fund	Ad Hoc Grant Reviewer	2007
Biological Sciences Committee and Cancer Research UK	Ad Hoc Grant Reviewer	2010
Wellbeing of Women Research Grant UK	Ad Hoc reviewer	2010
Cancer Research UK	Ad Hoc Reviewer	2011
Cancer Research UK	Ad Hoc Reviewer	2012
European Commission:	Expert reviewer	2012

FP7 Innovation Program on Cancer Metastasis First Stage Consensus Panel, Brussels European Commission Horizon 2020	Expert Reviewer	2014
First Stage Panel European Commission Horizon 2020	Expert Reviewer	2015
Consensus Panel	Expert Reviewer	2017

III C) CANCER CENTER

Indiana University Simon Cancer Center Experimental and Developmental Therapeutics Program

	Program Co-leader	2007-2015
Scientific Review Committee	Member	2005-2015
Review Committee for Prostate Cancer Pilot Project	Member	2004
Scientific Poster Evaluation, Indiana University Cancer Center Research Day	Judge	2006
Review Panel for IUCR ITRAC proposals IU-Purdue RFA	Member	2007
Review Panel for Lung Cancer Working Group	Member	2008
Review Panel for IUCR ITRAC proposals	Member	2008
Review Panel for ARRA NHLBI P30 proposals	Member	2009
Review Panel for Peugh Scholar Nomination	Member	2009
Review Panel for IU-Purdue Cancer Working Group Program	Member	2010
Panel for review usage of specimens from IUSCC Tissue Bank	Reviewer	2012-2015
Review Panel for Clinical Trial Correlative Pilot Funding, IUSCC	Member	2010
IUSCC-EDT Program Retreat	Chair	2010
Review Committee for the IUSCC Translational Core Facility	Chair	2011-2015
Review Panel for Basic Science Pilot Funding, ITRAC	Member	2010
Review Committee for IUPUI Research Support Funds Grants, (biannual reviews)	Member	2010-2016
IUSCC-EDT Program Retreat	Chair	2011
IUSCC-EDT Program Retreat	Chair	2012
IUSCC-EDT Program Retreat	Chair	2015

Robert H. Lurie Comprehensive Cancer Center Translational Research in Solid Tumors Lurie Cancer Center

	Program Leader	2023-
Translational Research in Solid Tumors Lurie Cancer Center	Program Co-Leader	2017-2022
Translational Bridge Program Lurie Cancer Center	Leader	2023-
Translational Bridge Program Lurie Cancer Center	Co-Leader	2016-2022
Women's Cancer Program	Program Co-Leader	2016-2017
Scientific Review Committee	Member	2016-2018
Lynn Sage Program Grant review	Reviewer	2016-present
Translational Bridge Grant review	Reviewer	2016-present

AbbVie Translational Grant Program	Reviewer	2017-present
TRIST Program Symposium	Co-Chair	September 2017
Oversight Committee for Tissue Path Core	Member	2017-present
NCTN Oversight Committee	Member	2016-2019
NCTN LAPS Grant	Co-PI	2019-present
LCC Annual Symposium	Chair	2019
LCC Bridge Program Annual Symposium	Co-Chair	2018
LCC Bridge Program Annual Symposium	Co-Chair	2019
LCC Bridge Program Annual Symposium	Co-Chair	2020
LCC Bridge Program Annual Symposium	Co-Chair	2021, 2022, 2023
TRIST Program Biennial Symposium	Co-Chair	2020, 2022, 2024

III D) MEDICAL SCHOOL

Indiana University

Scientific Poster Evaluation, Biochemistry Research Day	Judge	2004
Search Committee for the Department of Obstetrics-Gynecology Chair	Member	2006-2007
Institutional Review Board (IRB-02)	Member	2005-2010
Search Committee for ACOS for Research at the VA Roudebush Hospital	Member	2010
Scientific proposals using tissue from the Komen Breast Cancer Tissue Bank	Reviewer	2010-2015
Search Committee for Biochemistry, Director for Center for Cancer Biology and Drug Discovery	Member	2012-2015

Northwestern University

Northwestern University Promotion and Tenure Committee	Member	2019-2023
Northwestern University Shared Facilities Overview Committee	Member	2020-2023

III E) DEPARTMENT

<u>Activity</u>	<u>Role</u>	<u>Dates</u>
Review Panel for Scientific Abstracts for Internal Medicine residents	Member	2007
Review Panel for Scientific Abstracts for Internal Medicine residents	Member	2008
Search Committee for Chief of the Division of Gynecology-Oncology	Member	2009
Department of Medicine Research Committee,	Member	2010-2015
Search Committee for Director of Phase I Program,	Member	2010-2014
Review Panel for Scientific Abstracts for Internal Medicine residents	Member	2012
Department of Medicine Grand Rounds Advisory Committee	Member	2011-2014
Search Committee for Chief of the Division of Gynecology-Oncology	Member	2013-2015
Promotion and Tenure Committee Department of Medicine	Member	2014-2015
Northwestern University Department of Obstetrics and Gynecology	Chair	2019

Search Committee Department of Medicine	Member	2017-2018
Search Committee Department of Surgery	Member	2018
Search Committee for Chief of Thoracic Surgery Department of Pharmacology	Member	2022
Search Committee for Breast Cancer Investigator		

III F) PATIENT CARE/CLINICAL SERVICE:

2002-2015: Indiana University

- Medical oncology outpatient clinic for women with gynecologic cancers; Indiana University Simon Cancer Center and IU Health University Hospital (one day/week)
- General oncology outpatient clinic at VA Roudebush Hospital, Indianapolis(1/2 day/week)
- Oncology consult service attending at VA Roudebush, Indianapolis (1-2 4 weeks blocks per year)
- Oncology service attending at IU Health University Hospital, Indianapolis (2 weeks per year)
- Interim Director of the Phase I Program IU Simon Cancer Center (August 2012-Sept. 2013)

2016-present: Northwestern University

- Medical oncology outpatient clinic for women with gynecologic cancers; Lurie Cancer Center and Northwestern Medicine, Chicago (one day/week)
- General oncology outpatient clinic at Jesse Brown VAMC, Chicago (1/2 day/week)
- Oncology consult service attending at Jesse Brown VAMC, Chicago (4-6 weeks per year)

III G) COMMUNITY:

Provided educational lectures on clinical and research topics to patient support communities and participated as speaker at fundraising events for cancer research. Selected events are highlighted:

--Vera Bradley Foundation, South Bend	2005; 2008
--Ovar' Coming Together Foundation, Indianapolis	2009
-- ACS Relay for Life, Indianapolis	2007, 2008, 2011
--American Cancer Society, Palm Beach Chapter	2011
-- Ovarian Cancer Research Foundation Alliance, National Meeting, Chicago,	2017
-- Lynn Sage Foundation, Chicago	2017-2019
--H Foundation, Chicago	2017-2019
-- Survive and Thrive, Prentice Hospital, Chicago	2017; 2019; 2020, 2021, 2023, 2024
--University of Chicago Patient Outreach Meeting	2020; 2023

IV) CLINICAL TRIALS:

Chair for investigator initiated clinical trials

Study Chair for National Clinical Trials:

- 1) A Phase II Evaluation of BAY 43-9006 (NSC #724772) for the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Cancer (Sponsors: NIH/CTEP). **Gynecologic Oncology Group 170F; completed**
- 2) A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer; ongoing (Sponsor: Astex) Lead PI (designed protocol in collaboration with sponsor); **completed**
- 3) A phase III Randomized Clinical Trial of chemotherapy (paclitaxel and carboplatin) versus chemotherapy and volume directed radiation therapy for Stage III and IVA optimally debulked endometrial cancer. (Sponsor: **Gynecologic Oncology Group 258 (Sponsors: NIH/CTEP); completed**
- 4) A Phase II Clinical trial of carboplatin, paclitaxel and pembrolizumab for advanced stage endometrial cancer (Sponsor: Merck, Big Ten Research Consortium); **completed**

Institutional or Regional Clinical Trials

- 1) Hoosier Oncology Group: Imatinib mesylate (Gleevec, STI571) in combination with docetaxel for the treatment of platinum-refractory ovarian cancer and primary peritoneal carcinomatosis, A Hoosier Oncology Group Clinical Trial (Gyn 03-62); **completed**
- 2) Hoosier Oncology Group: A Phase 2, Open-Label, Safety and Efficacy Study of Panzem[®] Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer; **completed**
- 3) Hoosier Oncology Group: Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111; **completed**
- 4) Hoosier Oncology Group: Phase I/II BNC105P combination study in partially platinum sensitive ovarian cancer patients in first or second relapse; Protocol Number ANZGOG-1102, **completed**
- 5) Hoosier Oncology Group: A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin in Combination with BIBF 1120 in Patients with Ovarian Cancer: Hoosier Oncology Group GYN10-149; **completed**
- 6) A Phase I/II Clinical Trial of Decitabine and Carboplatin in Patients with Platinum Resistant Ovarian Cancer—IU- 149 (Sponsor: National Cancer Institute- Quick Trial); **completed**
- 7) A Phase II Clinical trial of Guadecitabine and Pembrolizumab in patients with Platinum Resistant Ovarian Cancer—NU Gyn 16-03 (Sponsor: Merck, Department of Defense); **completed**
- 8) A Phase II Clinical Trial of Tivozanib in Patients with Platinum Resistant Ovarian Cancer—NU Gyn 15-02 (Sponsor: NCCN); **completed**

Institution Principal Investigator for numerous clinical trials (not listed, more than 80 trials completed; 6-10 trials active)

V) TEACHING/MENTORING:

TEACHING AND CURRICULUM DEVELOPMENT:

Hematology Oncology Fellows Core Lectures in Gynecologic Oncology	2003-present
Gynecology Oncology Fellows Core Lectures on Ovarian Cancer	2016-present
Graduate Faculty-Biochemistry and Molecular Biology, IUSM	2007-2015
Member Driscoll Graduate Program, Northwestern University	2016-present
Lecturer in Cancer Biology Course Driscoll Graduate Program	2016-present
Lecturer in Masters in Reproductive Sciences Program	2016-present
Translational Bridge Initiative—Postdoctoral Training Program (Co-Chair)	2016-present

Mentees:

URM

Graduate Students:

PhD Thesis Advisor:

Indiana University Biochemistry and Molecular Biology

Liyun Cao	2008-2012	
	Thesis Defense March 2012	(now Assistant Professor at UAB)
Jiyoon Lee	2010-2015	
	Thesis Defense August 2015	(now post-doctoral fellow at Harvard Univ)

Northwestern University Driscoll Graduate Program

Yaqi Zhang	2018-2022	
	Thesis Defense May 2022	(now consultant at Bane)
Guangyuan Zhao	2017-2022	
	Thesis Defense August 2022	(now scientist at Tempus)
Russel Keathley	2020-2023	
	Thesis Defense August 2023	(now consultant at Medcixi)

Research Elective:

Liyun Cao	PhD student Biochemistry	Feb-April 2008
Jyothi Mondrovani	PhD student Biochemistry	Feb-April 2008
Chambliss Daphne [#]	Masters Life Science Program	Jan-April 2009
Jiyoon Lee	Biochemistry	Feb-April 2011
Yara Rodriguez	Driscoll Graduate Program	Feb-May 2017
Guangyuan Zhao	Driscoll Graduate Program	June-July 2017
Yaqi Zhang	Driscoll Graduate Program	March-June 2018
Hanna Kubo	Driscoll Graduate Program	Sept-Nov 2018
Ilka Lorenzo	Driscoll Graduate Program	Sept-Nov 2022

PhD Thesis Committee Member Driscoll Graduate Program

Yara Rodriguez (Abdulakir Lab)
Rokana Taftaf (Liu Lab)
Yarong Li (Davuluri Lab)
Mihai Truica (Abdulakir Lab)
Emma Shuster (Liu Lab)
Alex Duval (Adli Lab)
Jane Frederick (Backman Lab)

Masters in Reproductive Sciences Thesis Advisor (Northwestern University)

Hiebin Roh	Thesis Advisor	2017-2019
Jenna Jacobi	Non-thesis advisor	2023

Medical Students

Gayathri, Suresh	MS3	Clinical research mentor	2008-2009
Stacy Hollar	MS2	Summer Research Program in Academic Medicine	2009

Nuria Mercadal Rosa	MS2	Awarded the William and Fern Groves Hardiman Scholarship Award	
Cassidy Overpeck	MS2	Summer Research Program in Academic Medicine	2010
		Summer Research Program in Academic Medicine	2011
Samantha Armstrong	MS2	Awarded, the William and Fern Groves Hardiman Scholarship Fund	
Katie Meyer	MS2	Summer Research Program in Academic Medicine,	2012
		Summer Research Program in Academic Medicine,	2013
		Prize for Poster Presentation; Research Presentation and AMWA 2014	
	MS3	Awarded the Will Wright fellowship for Research	2014-2015
Clarence Chun	MS3	Research Project and NCTN grant	2018-2019

Undergraduate Students:

Alice Ji		June-July 2008	
Shelby Mullin		June-July 2009	
Hannah Patrick		June-July 2009 Howard Hughes Medical Institute Precollege Program	
Sarbajeet Nagdas		June-July 2012 Summer Engineering Research Program (completed Md/PhD Program at UVA; awarded F32 Fellowship)	
Janice Zhao		June-July 2013 Summer Engineering Research Program (Admitted to Medical School)	
Kelton Mock		June-July 2014 Summer Engineering Research Program, 12 weeks	
George Hutchins [#]		July-August 2017 Summer CURE Program	
George Hutchins [#]		July-August 2018 Summer CURE Program, (admitted to Harvard Medical School)	
Adam Vieth		June-July 2022	
Elise Liu		June-July 2022	
Ritaj Abdulakhir [#]		June-July 2022	
Natalia Obrochta		June-July 2023 (Weinberg grant)	
		June-July 2024 (Weinberg grant)	
Natalia Masnica		August-September (Weinberg grant)	
Ellie Siu		June-July 2023 (Weinberg grant)	
Audrey Matei		July 2023	

Residents

Jordan Schmitt, MD	Research elective	Dec 2007
Aruna Gavini, MD	Research elective	Feb-June 2008
Ntukogu Obiageli, MD [#]	Research elective	Feb 2009
Waddah Arafat, MD	Laboratory rotation	Nov 2012
Jason Meyer, MD	Laboratory rotation	Sept 2014

Fellows:

Jordan Schmitt, MD	Hematology Oncology fellow Currently faculty at VAMC Roudebush	2011-2012
Maria DeLeon, MD	Gynecology Oncology Fellow Currently faculty at City of Hope	2013-2014
Jessica Thomes Peppin, MD	Gynecology Oncology fellow	2014-2015
Mathew Cowan, MD	Gynecology Oncology fellow	2018-2019

Postdoctoral fellows:

Minati Satpathy, PhD	Postdoctoral fellow (now scientist at Georgia Tech Institute)	2006-2009
Minghai Shao, PhD	Postdoctoral fellow	2009-2012
Bakhtior Yakubov, PhD	Postdoctoral fellow	2011-2015
Salvatore Condello, PhD	Postdoctoral fellow	2012-2015
Livia Sima, PhD	Postdoctoral fellow (now Research Scientist at Institute of Biochemistry, Bucharest)	2016-2018
Nikky Nwani, PhD [#]	Postdoctoral fellow (now SRO at Department of Defense)	2016-2018

Yinu Wang, PhD	(T32 postdoctoral fellowship) Postdoctoral fellow	2017-2022
Andres Valdivia, PhD#	(OCRFA postdoctoral fellowship) Postdoctoral fellow	
Valery Adorno Cruz, PhD#	(OCRA post doctoral fellowship) Postdoctoral fellow	2019-2024 2020-2021
Ana Maria Isac, PhD	(NCI fellowship) Post doctoral fellow	2022-2025
Junzui Li, PhD	Postdoctoral fellow	2024-present

Junior Faculty:

Mathew Strother, MD	Assistant Professor, Hematology Oncology	2010-2012
Horacio Cardenas, PhD#	Research Assistant Professor, non-tenure track	2011-present
Safi Shahda, MD	Assistant Professor, Hematology Oncology	2013-2016
Qing Yu, PhD	Research Assistant Professor, non-tenure track	2014-2015
Shadia Jalal, MD	Assistant Professor, Hematology Oncology	2012-2016
Emma Barber, MD	Assistant Professor, tenure-track Gynecology (new mentored award from the Gynecology Oncology Group Foundation)	2017-present
Mario Pineda, MD PhD	Assistant Professor, tenure-track Gynecology	2015-2017
Cesar Santa Maria, MD#	Assistant Professor, Hematology Oncology	2015-2017
Hao Huang, PhD	Research Assistant Professor, non-tenure track	2016-present
Thanh Delliger, MD	Assistant Professor City of Hope	2017-2021
Salvatore Condello, PhD	Research Assistant Professor, non-tenure track (now tenure track Assistant Professor at Indiana University, new mentored Department of Defense Award)	2016-present
Dario Roque, MD#	Assistant Professor, non-tenure track	2020-present

VI) INVITED PRESENTATIONS

NATIONAL/INTERNATIONAL

Title	Organization	Date
Gene Expression Profiling in Ovarian Carcinoma	Jonsson Cancer Center Research Seminar, UCLA	November 2002
Gene Expression Profiling in Ovarian Carcinoma	Hematology Oncology Grand Rounds University of Kentucky	December 2002
Ovarian Cancer: Genechips Applied	Hematology Oncology Grand Rounds University of Chicago	February 2004
Patients With Platinum Sensitive Recurrent Ovarian Cancer Should NOT Receive Carboplatin and Paclitaxel	Gynecology Oncology Group: Controversies in Gynecologic Malignancies Mini-Symposium	July 2004
Rare Ovarian Tumors	Third Annual Oncology Congress San Francisco	September 2007
Maintenance Therapy in Ovarian Cancer: A Clinical Debate	Third Annual Oncology Congress San Francisco	September 2007
How to Set Up a Successful Laboratory How to develop and Re-Develop Your Grant Successfully	ACS Career Development Conference for Beginning Investigators	November 2007
PDGFR is Destabilized by Geldanamycin in Cancer Cells	Harry and Elsa Jiller ACS Professors Meeting	November 2007
VEGF and other Targets in Ovarian Cancer	International Symposium on Anti-Angiogenic Agents, San Diego, CA	January 2009
Chemotherapy and Radiotherapy for Locally Advanced Endometrial Cancer	The 4th Korean GOG Meeting Baltimore, MD	July 2009
Peritoneal metastasis in Ovarian Cancer	UCSF Obstetrics and Gynecology Grand Rounds	September 2009
Sorafenib in Ovarian Cancer	Clinical Investigators Forum	October 2009

Epigenetic Therapies in Ovarian Cancer	Chicago, IL Ohio State University- Epigenetic Therapy Meeting	November 2009
Role of PDGFR in Ovarian Cancer	Investigators Meeting sponsored by ImClone, New York	January 2010
Role of Radiotherapy for Locally Advanced Endometrial Cancer	The 5th Korean GOG Meeting San Diego, CA	January 2010
Combined Modality Therapy for Locally Advanced Endometrial Cancer-Con Side Debate	The 7th International Congress on Ovarian Cancer and Other Gynecologic Malignancies, New York, NY	March 2010
Tissue Transglutaminase in Metastasis	First Gordon Research Conference on Transglutaminases in Human Disease Davison College, NC	July 2010
Rationale for Anti-Angiogenic Treatment in Ovarian Cancer	Conversations in NSCLC, Breast and Ovarian Cancer, Vienna, Austria	October 2010
Endometrial Cancer: State of Affairs	10th Annual Clinical Cancer Course Lake Tahoe, CA	January 2011
Decitabine as a Chemosensitizer in Ovarian Cancer	Investigators Meeting Salt Lake City, UT	April 2011
Phase I/II Trial of Decitabine and Carboplatin in Platinum Resistant Ovarian Cancer	ASCO Annual Meeting Chicago, IL	June 2011
Advances in Gynecologic Oncology: ASCO 2011	Best of ASCO Review Course Miami, FL	July 2011
Advances in Gynecologic Oncology	Best of ASCO Review Course Bratislava, Slovakia	September 2011
Tissue Transglutaminase induces EMT and Metastasis in Ovarian Cancer	Harry and Elsa Jiler ACS Professors Meeting MD Anderson Cancer Center Invited Seminar, Houston, TX	October 2011
Novel Targets in Ovarian Cancer	Gynecologic Oncology Group Scientific Symposium, Boston, MA	March 2012
PARP Inhibitors: The Future	Second Gordon Conference on Transglutaminases Davidson College, NC	July 2012
The Role of Intra- and Extra-cellular TG2 in Ovarian Cancer Metastasis	Astex Investigators Meeting Scottsdale, AZ	July 2012
Decitabine Resensitizes Ovarian Cancer to Chemotherapy	ASCO Annual Meeting Chicago, IL	November 2012
Ovarian Germ Cell Tumors: Principles of Therapy	ASCO Annual Meeting Chicago, IL	June 2013
Rare Ovarian Tumors- Poster Discussion	ASCO Annual Meeting Chicago, IL	June 2013
Epigenetic Interventions in Ovarian Cancer	Curso de Cancer University of Concepcion, Chile	January 2014
Epigenetic Interventions in Ovarian Cancer	Satellite Symposium Cancer Biology: From Basic to Clinic Santiago, Chile	January 2014
The TG2/Integrin β 1/Fibronectin Complex is a Target in Ovarian Cancer	Third Gordon Conference on Transglutaminases, Barga, Italy	June 2014
Adjuvant Therapy for stage III/IVA Endometrial Cancer	2014 GYN School Co-sponsored by ABS, ASCO, ASTRO and SGO	July 2014
GOG 258 Current State	The 14-th Korean GOG Meeting University of Illinois at Chicago	July 2014
Tissue Transglutaminase/Integrin Complex in Ovarian Cancer	Cancer Center Seminar, Chicago	October 2014
Tumor Stroma Interaction and Other Emerging Targets in Ovarian Cancer	Northwestern University, Chicago	March 2015
Tissue transglutaminase in Cancer	Gordon Conference on	July 2016

Tumor Stroma Interaction and Other Emerging Targets in Ovarian Cancer	Transglutaminases, Girona, Spain Mayo Clinic, Rochester	July 2015
New Targets of Ovarian Cancer Stem Cells	Purdue University, West Lafayette	February 2016
New Developments in Ovarian Cancer	Grand Rounds, West Los Angeles VA	March 2017
Epigenetic Targeting in Ovarian Cancer	Stop Cancer, Bucharest, Romania	April 2017
Adjuvant Chemoradiation in Stage III/IVA Endometrial Cancer-GOG258	ASCO National Meeting, Chicago	June 2017
Updates in Gynecologic Cancer	Post ASCO Course, Cluj, Romania	June 2017
Ovarian Cancer Stem Cells- Link to Endometriosis	Endometriosis Foundation New York, NY	October 2017
New Targets in Cancer Stem Cells	MDACC, Experimental Therapeutics Program Seminar, Houston, TX	March 2018
Novel Targets in Cancer Stem Cells	Ohio State University Cancer Center Columbus, OH	Sept 2018
Cancer Stem Cells from Hype to Hope	Oklahoma University Cancer Center Oklahoma City, OK	March 2019
Novel Targets in Ovarian Cancer	Stop Cancer, Bucharest, Romania	April 2019
Future of Oncology—A Dialogue	Purdue University, West Lafayette	Sept 2019
Cancer Stem Cells from Hype to Hope	University of Chicago Grand Rounds Chicago, IL	November 2019
Ovarian Cancer Stem Cells	Medical University of South Carolina, Charleston, SC	December, 2019
Epigenetic therapies in ovarian cancer: How does the tumor microenvironment respond?	AACR Educational Symposium	June 2020
ASCO Updates in Gynecologic Oncology	Post ASCO Review, Cluj, Romania	July 2020
Ovarian Cancer Stem Cells: From Hype To Hope	Stop Cancer, Bucharest Romania	October 2020
Endometrial Cancer: Looking Froward	Romanian Oncology Congress	October 2020
New Targets in Ovarian Cancer	AACR National Meeting	April 2021
Drivers and Suppressors of Cancer Stem Cells	Grand Rounds UPMC	May 2021
Chemotherapy for Endometrial Cancer	SGO Journal Club	June 2021
Advances in Endometrial Cancer	HAGO Symposium	September 2021
Ferroptosis in Resistant Ovarian Cancer	Stop Cancer, Bucharest Romania	October 2021
New Trends in Endometrial Cancer	Romanian Oncology Congress	October 2021
Developing Budgets for Translational Cancer Grants and Trials	ETCTN Educational Program	October 2021
ASCO Updates in Gynecologic Oncology	Post ASCO Review, virtual	July 2022
Treatment Advances in Endometrial Cancer	Romanian Congress of Oncology Brasov, Romania	October 2022
UPR in Ovarian Cancer Stem Cells	Midwestern Ovarian Cancer Summit Minneapolis, MN	November 2022
Metabolic Targets in Ovarian Cancer Stem Cells	Grand Rounds Cornell University New York, NY	December 2022
Metabolic Targets in Ovarian Cancer	University of Nebraska Cancer Center Grand Rounds (virtual)	February 2023
Chemoradiotherapy in Locally Advanced Endometrial Cancer	SGO Plenary Session	March 2023
Metabolic Targets in Ovarian Cancer	UNC Lyneberger Cancer Center Symposium, Chapel Hill, NC	April 2023
The Balance between Saturated and Unsaturated fats in Ovarian Cancer	STOP Cancer (virtual)	April 2023
Metabolic Targets in Ovarian Cancer	Ovarian Cancer Syndicate (virtual)	May 2023

ASCO Updates in Gynecologic Oncology Metabolic Targets in Ovarian Cancer	Post ASCO Review, virtual Romanian Biochemistry Society National Congress, Cluj, Romania	June 2023 September 2023
Metabolic Targets in Ovarian Cancer Epigenetic Priming and Immunotherapy In Ovarian Cancer	University of California Irvine AACR Ovarian Cancer, Boston, MA	October 2023 October 2023
Metabolic Targets in Ovarian Cancer Precision Medicine in Gynecologic Cancer Epigenetic IO Combinations in Cancer Metabolic Targets in Ovarian Cancer TG2 a Controversial Cancer Target	Mott Center Symposium, Detroit, Mi Romanian Congress of Oncology ESMO-Immunology, Geneva, Switzerland Mays Cancer Center Grand Rounds FEBS conference on transglutaminases Bertinoro, Italy	October 2023 October 2023 December 2023 April 2024 May 2024
ASCO Updates in Gynecologic Oncology Multidisciplinary Approach to Endometrial Cancer	Post ASCO Review, virtual Romanian Congress of Oncology	September 2024 October 2024
Lipid Metabolism Alteration in Ov. Cancer Ovarian Cancer: Why Lipids Matter	STOP Cancer, Bucharest, Romania Grand Rounds Univ of Nebraska	April 2025 April 2025

LOCAL/REGIONAL (selected lectures listed)

Title	Organization	Date
Novel Therapy for Ovarian Cancer	IUSCC Experimental Therapy Program	April 2003
Targeted Therapy for Ovarian Cancer	IUSCC Grand Rounds	June 2003
PDGFR α as a therapeutic target in Ovarian Carcinoma	Walther Oncology Center	June 2003
Angiogenesis and Targeted Therapy for Breast Cancer	Breast Cancer Symposium	January 2004
Genechips: From Bench to Bedside	IUSCC Grand Rounds	May 2004
Her 2 neu targeted therapy: Topic of Debate	Hoosier Oncology Group Semi-Annual Meeting, Indianapolis	January 2005
Gynecologic Malignancies	ASCO Review Course, Indianapolis	June 2005
Ovarian Cancer: Progress and Challenges	Purdue University, West Lafayette	August 2005
Transglutaminase in Ovarian Cancer	The 13th Annual ACS Great Lakes Symposium	Oct 2005
Angiogenesis and Targeted Therapy PDGFR and Transglutaminase, Novel Targets in Ovarian Cancer	Breast Cancer Symposium, Indianapolis Indiana University, Bloomington, IN	Jan 2006 Feb 2006
Novel Targets in Ovarian Cancer	IUSCC Grand Rounds, Indiana University	April 2006
Tissue Transglutaminase and PDGFR, novel Targets in Ovarian Cancer	Walther Oncology Center Seminar	May 2006
Gynecologic Malignancies	ASCO Review Course, Indianapolis	June 2006
Peritoneal Metastasis: Nuts, Bolts and Sticky Glue	IUSM Biochemistry Weekly Seminar	Jan 2007
Her 2 neu Directed Therapy in Breast Cancer	Grand Rounds Indiana University School of Medicine	March 2007
Transglutaminase in Ovarian Cancer	Walther Oncology Institute Seminar Series	May 2007
Sorafenib in Ovarian Cancer	Investigators Meeting, Chicago	May 2007
Advances in Gynecologic Oncology	ASCO Review Course, Indianapolis	July 2007
Transglutaminase in Peritoneal Metastasis	Research Seminar, VAMC Roudebush, Indianapolis	Oct 2007
Quick Trials: Lost in Translation	Experimental and Developmental Therapeutics Program IUSCC	Nov 2007
How Tumors Form	Dept. of Obstetrics and Gynecology Grand Rounds, IUSM	Jan 2008

Advances in Gynecologic Oncology Peritoneal Metastasis: Nuts, Bolts and Sticky Glue	ASCO Review Course, Indianapolis IUSCC Grand Rounds	July 2008 Sept 2008
Tissue Transglutaminase in Ovarian Cancer	Showalter Trustee Board Presentation	Oct 2008
Peritoneal Environment and Metastasis Ovarian Cancer: A Biology-Based Map to Treatment	IUSCC Tumor Biology Retreat Department of Medicine Grand Rounds IUSM	April 2010 April 2010
A Biological Guide to Ovarian Cancer Treatment	IUSCC Grand Rounds	April 2010
Advances in Gynecologic Oncology Ovarian Cancer	ASCO Review Course, Indianapolis Grand Rounds St. Mary's Hospital Evansville, IN	July 2010 Sept 2010
Advances in Ovarian Cancer	Grand Rounds Methodist Hospital Henderson, KY	Sept 2010
Miss Gee: Truth or Fiction	IUSCC Grand Rounds	April 2011
Rare Ovarian Tumors	Grand Rounds, Reid Hospital	May 2011
Advances in Gynecologic Oncology	ASCO Review Course, Indianapolis	July 2011
Advances in Gynecologic Oncology	ASCO Review Course, Indianapolis	July 2012
Functions of Tissue Transglutaminase in Ovarian Cancer	Invited Seminar for the Department of Molecular Medicine and Genetics, IUSM	Dec 2012
Ovarian Cancer: Are we there yet?	Department of Medicine Grand Rounds	Jan 2013
New Interventions in Ovarian Cancer Therapy	IUSCC Cancer Research Day	May 2013
Epigenetic Therapies in Ovarian Cancer	Walther Cancer Institute Symposium Notre Dame University, South Bend, IN	May 2013
Advances in Gynecologic Oncology	ASCO Review Course, Indianapolis	July 2013
Advances in Breast Cancer Therapy	VAMC Roudebush Grand Rounds	Sept 2013
Tissue Transglutaminase in Ovarian Cancer	VAMC Research Seminar	Oct 2013
Ovarian Cancer: New Approaches?	Endocyte Grand Rounds West Lafayette, IN	March 2014
Tissue Transglutaminase is a Target In Ovarian Cancer	IIEEOCC Second Symposium Notre Dame University, South Bend, IN	June 2014
Dual Roles of TG2 in Ovarian and Pancreatic Cancer	IUSCC Tumor Microenvironment Program	Dec 2014
K99-R00 Award	IUSM Graduate Student Seminar	Feb 2015
Ovarian cancer Are we there yet?	IUSM MD PhD Seminar	May 2015
From Bench to Clinic: My Journey	IUSM Summer Research Program	June 2015
Clinical Trials in Gynecology Oncology	Survivorship Course, Chicago, IL	Sept 2016
Do Ovarian Cancer Stem Cells Have An Achilles Heel?	Translational Science Lecture Northwestern University	Jan 2017
Updates in Ovarian and Cervical Cancer	Masters in Reproductive Science	Feb 2017
New Developments on Ovarian Cancer	Dupage Hospital, IL	Feb 2017
Novel Targets of Ovarian Cancer Stem Cells	LCC TRIST Symposium	Feb 2017
Metastasis and Cell Migration	Driscoll Graduate Program	May 2017
Updates in Gynecology Oncology	ASCO Review Course Chicago IL	July 2017
Immunotherapy and PARP Inhibitors	Survive and Thrive Symposium	Sept 2017
Updates in Gynecology Oncology	ASCO Review Course Chicago IL	July 2018
Updates in Gynecology Oncology	ASCO Review Course Indianapolis IN	July 2018
Updates in Gynecology Oncology	ASCO Review Course Chicago IL	July 2019
Updates in Gynecology Oncology	ASCO Review Course Indianapolis IN	July 2019
Immunotherapy and PARP Inhibitors	Survive and Thrive Symposium	Sept 2019
Tissue Transglutaminase Fibronectin Interaction-A New Target in Cancer	Biotech by the Lake, Chicago, IL	May 2020

Platinum Resistant Ovarian Cancer Cells Are Susceptible to Ferroptosis	LCC TRIST Meeting	March 2021
Epigenomic Priming Enhances Response to Immunotherapy in Ovarian Cancer	LCC Translational Bridge Symposium	November 2021
Metabolic Targets in Ovarian Cancer	LCC TRIST Meeting	November 2022
Clinical Trials in Ovarian Cancer	Survive and Thrive Symposium	September 2023
Metabolic Targets in Ovarian Cancer	LCC Grand Rounds	December 2023
Cholesterol Targeting on PROC	LCC TRIST Symposium	January 2024
Emerging Targets in PROC	LCC Special Seminar	July 2024
Clinical Trials in Ovarian Cancer	Survive and Thrive Symposium	September 2024
Ovarian Cancer: Why Lipids Matter	Antonio Scommegna Symposium UIC, Chicago, IL	November 2024